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of the elevated zero maze and the influence of age-related differences on behavior. Major 
Professor: Melloni N. Cook, Ph.D. 
 
Anxiety disorders affect a significant proportion of the population and can be debilitating 
in some circumstances. The exact etiology of these disorders remains to be determined 
and animal models are an important part of that effort. The elevated zero maze, a 
behavioral measure of anxiety, was introduced as an alternative to the popular elevated 
plus maze. While the elevated zero maze has been pharmacologically validated in rats, 
the available data in mice is more limited. Similarly, the data available on anxiety-like 
behavior in adolescent mice lacks breadth despite considerable evidence suggesting that 
developmental processes during this period play a role in the etiology of anxiety 
disorders. In order to extend the available pharmacological data on the elevated zero 
maze and clarify age-related differences in anxiety-like behavior, three experiments using 
C57BL/6J and DBA/2J mice were performed. Experiments 1 and 2 examined the effects 
of chlordiazepoxide and a serotonin norepinephrine reuptake inhibitor on anxiety-like 
behavior in these strains. Experiment 3 examined age-related differences between these 
strains in anxiety like behavior during periadolescence, adolescence, and late 
adolescence. Anxiety-like behavior was found to vary with strain, task, drug, and age. 
These data extend our knowledge of baseline behavior in these stains and extend the 
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Anxiety-Like Behavior in C57BL/6J and DBA/2J Mice: Pharmacological 
Characterization of the Elevated Zero Maze and the Influence of Age-Related 
Differences on Behavior. 
 It is estimated that each year 40 million adults in the United States suffer from 
anxiety disorders, presenting a significant burden to both patients and society as a whole 
(NIMH, 2007). Included in the class of anxiety disorders are: panic disorder, obsessive-
compulsive disorder, post-traumatic stress disorder, social phobia, specific phobias, and 
generalized anxiety disorder (NIMH, 2007). While the symptoms of these disorders vary 
widely both between and within disorders, they all share the common attribute of being 
characterized by excessive, irrational fear and worry (NIMH, 2007).Though the exact 
causes of these disorders are not clear, overarching estimates based on twin and adoption 
studies reveal that approximately 30% of the variability in anxiety traits can be explained 
by genetic factors, with estimates of heritability between .3-.5 (Clement et al., 2002). 
This moderate heritability suggests that these disorders are complex traits involving 
multiple, interacting genetic factors and experiential factors. To date, a diathesis-stress 
model has largely been used to explain their etiology. Briefly, this model suggests that 
some individuals have genetic/ biological traits rendering them vulnerable to the negative 
effects of stress, and if a sufficient stressor or series of stressors are experienced, a 
pathological state may then ensue. A large body of literature has documented the effects 
of various stressors and biological factors on the development of anxiety disorders in 
humans and anxiety-like behavior in animal models (for reviews see: Lesch, 2001; 
Clement et al., 2002; Finn et al., 2003; Gordon and Hen, 2004; Murray et al., 2009). 




remains incomplete, and animal models continue to be an important element in furthering 
our understanding. 
 Numerous animal models of anxiety-like behavior are available, and have been 
useful in the study of the biology and pharmacology of anxiety-like traits. The vast 
majority of these models were developed using rats. However, the use of mice in 
neuroscience research has become more widespread as they offer a greater opportunity to 
exploit genetic models. While many of the behavioral models developed for rats have 
been successfully „shrunken‟ down for use with mice, more pharmacological data on 
these models is available from rats than mice. As has been pointed out many times in the 
literature, mice are not simply little rats and considerable ethological and biological 
differences exist. Further, pharmacological research using mice has largely been 
performed using outbred strains, thereby reducing the range of conclusions that might be 
drawn from these investigations and limiting the ability to make assertions about the role 
of genetics in the phenomena under study (Taft et al., 2006). Despite their limited 
employment, inbred strains of mice provide a convenient tool for genetic research, and 
they have been shown to vary on a number of important traits including baseline behavior 
(e.g., Cook et al., 2001; Liu and Gershenfeld, 2003), response to antidepressant drugs 
(Crowley et al., 2005), monoamine concentrations in the brain (Jones et al., 1996), and 
structure of proteins involved in serotonin neurotransmission (Hackler et al., 2006). 
Additionally, the screening of inbred mouse strains is critical for the detection of 
background effects that often influence the interpretation of studies using transgenic mice 




of murine genetic models in anxiety research is to more fully characterize these 
behavioral models using inbred strains of mice.  
 Towards this aim, three experiments were performed using C57BL/6J (B6) and 
DBA/2J (D2) mice. Since its introduction in 1994 (Shepherd et al., 1994), the elevated 
zero maze (EZM) has garnered considerable use as a behavioral model of anxiety, and 
while it has been pharmacologically validated using rats, the extent of available 
pharmacological data on mice is limited. Therefore, the acute effects of a classical 
benzodiazepine, chlordiazepoxide (CDZ) on behavior in the EZM were examined. 
Additionally, very few antidepressants have been examined in the EZM despite their 
frequent use in the treatment of many anxiety disorders. Thus, the behavioral effects of a 
common serotonin norepinephrine reuptake inhibitor (SNRI) were examined as well. 
(The drug used was acquired from the pharmaceutical company holding rights to this 
drug, and a contractual agreement requires the pharmaceutical company to be allowed to 
review all presentations and publications of experiments using the drug provided. 
Unfortunately, this company collapsed during the recent economic crisis, and we were 
unable to meet our obligations. Therefore, this drug will be referred to as „SNRIX‟ in 
order to maintain confidentiality until said review or release from the agreement can be 
obtained.) Lastly, there is considerable evidence that anxiety traits and the propensity 
towards the development of anxiety disorders is shaped in early development and 
adolescence (vide infra), but the data on anxiety-like behavior in young mice is lacking as 
compared to that available in rats. Hence, the behavior of young mice in a number of 





Pharmacological Characterization of the Elevated Zero Maze 
 All currently available rodent models of anxiety examine an animal‟s behavior in 
response to an aversive stimulus or situation. The conditioned models of anxiety 
normally use some noxious stimulus such as electric shock, while the unconditioned 
models of anxiety examine rodents‟ natural tendency to explore a novel environment 
while avoiding situations that might be potentially dangerous (e.g., open/unprotected 
spaces, unfamiliar foods, etc.) Of the available unconditioned models, the elevated plus-
maze (EPM) is one of the most commonly used. The EPM consists of two alley-ways 
arranged perpendicularly at their center creating four arms and a central square. Two of 
these arms are enclosed by walls while the other two remain open. Generally rodents will 
explore both enclosed and open arms of the maze but spend a great deal more time in the 
enclosed arms, and time spent in the open versus closed arms and entries into the open 
arms have been pharmacologically validated as measures of anxiety-like behavior. 
However, there is ambiguity in interpreting time spent in the center intersection of the 
maze. To address this problem, Shepherd and colleagues (1994) developed the EZM.  
 The EZM consists of a circular runway with alternating open and closed 
quadrants. The circular design eliminates the ambiguity of the central square in the EPM 
and allows for uninterrupted ambulation, which might provide a more sensitive measure 
of anxiety-like behavior (Shepherd et al., 1994). It was initially shown that diazepam and 
CDZ decreased anxiety-like behavior in rats, while the anxiogenic compound 1-(m-
chloro-phenyl)piperazine (mCPP) increased anxiety-like behavior (Shepherd et al., 
1994). Since that time, a number of benzodiazepines at various doses have been shown to 




the EZM for mice was used to examine induced mutations (e.g., Heisler et al., 1998), and 
only later were the effects of classical anxiolytic (Bilkei-Gorzo et al., 2002) and 
anxiogenic (Bilkei-Gorzo et al., 2004) compounds demonstrated. Still, the range of drugs, 
doses, and mouse strains examined remains constricted (see Table 2). Further, only a few 
reports are available on the effects of antidepressant medications in the EZM in rats or 
mice (see Tables 1 and 2) despite these medications being the most common treatment 




Table 1. Effects of acute administration of standard anxiolytic and anxiogenic drugs in rats on the elevated zero-maze 
 
Drug Strain Dosages Tested 
Open 





Anxiolytics         
alprazolam Sprague- .005, .05, .005↓; .005 ↓;  NE  Bentué-Ferrer 
 Dawley .5 mg/kg IP .05, .5 NE .05, .5 NE    et al., 2001 
         
CDZ Sprague- .5, 1, 2 mg/kg SC 1, 2 ↑   .5, 2 ↑ .5, 2 ↓ Shepherd et al., 
 Dawley       1994 
  2.5, 5, 10 mg/kg IP 5, 10 ↑ 2.5, 5 ↑    Steckler et al., 
        2005 
  6 mg/kg SC ↑ NE  NE ↓ Weiss et al., 1998 
 Wistar 10 mg/kg PO ↑ ↑  ↑ ↓ Cryan et al., 2004 
         
diazepam Charles .25, .5, 1 mg/kg IP .5, 1 ↑   .5, 1 ↑ NE Ramanathan et al., 
 Foster       1998 
 Sprague- .125, .25, .5 ↑   .25, .5 ↑ .5 ↓ Shepherd et al., 
 Dawley .5 mg/kg SC      1994 
  .5 mg/kg SC ↑   ↑ ↓ Shepherd et al., 
        1996 
 Wistar 1, 2 mg/kg ↑ NE  2 ↑ NE Frankowska et al., 
        2007 
  .25, .5, 1, ≥ .5  ↑  NE NE ↓ Matto et al., 1997 
  2 mg/kg SC       
         
lorazepam Sprague- .015 mg/kg IP ↓ ↓  ↓  Bentué-Ferrer 
 Dawley       et al., 2001 
 





 Table 1. Effects of acute administration of standard anxiolytic and anxiogenic drugs in rats on the elevated zero-maze 
 
Drug Strain Dosages Tested 
Open 





buspirone Wistar .04, .2, 1,  NE  NE NE NE Matto et al., 1997 
  5 mg/kg SC       
         
desipramine Wistar 10, 20 mg/kg IP NE ↓ NE NE NE Pähkla et al., 2000 
         
fluoxetine Wistar 5, 10 mg/kg IP NE 10 ↓ NE 10 ↓ NE Pähkla et al., 2000 
         
Anxiogenics         
DMCM Sprague- .3 mg/kg IP ↓ (NS) ↓ (NS)  ↓  Bentué-Ferrer  
 Dawley       et al., 2001 
 Wistar .1, .5, 1,  NE  1.5 ↓ ↑ NE Matto et al., 1997 
  1.5 mg/kg IP       
  .5, 1.5 mg/kg IP ↓ ↓ ↑ ↓  Pähkla et al., 2000 
         
mCPP Sprague- .25, .5, 1 mg/kg SC .5, 1 ↓   1 ↓ .5, 1 ↑ Shepherd et al.,  
 Dawley       1994 
 
For the behavioral measures (open time, activity, latency [LAT], head dip, and stretch attend), doses producing observed effect are 
reported where the effect was dose dependent. Blank cells indicate that the measure was not reported by the authors. Open time refers 
to time spent in open quadrants of the maze (percentage or actual as reported by authors). Activity refers to locomotor activity in the 
maze as reported by authors. Latency (LAT) refers to latency to first enter an open quadrant of the maze. Head dip refers to 
observations of the animal dipping its head over the edge of the open quadrants of the maze. Stretch attend refers to observations of 
animals adopting a stretched-attend posture, typically defined as an elongated posture with the snout stretched forward. CDZ = 
chlordiazepoxide, DMCM = methyl-6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate, mCPP = m-chlorophenyl-piperazine, IP = 
intraperitoneal injection, SC = subcutaneous injection, PO = per os administration, ↑ = increase in measure, ↓ = decrease in measure, 





Table 2. Effects of standard anxiolytic and anxiogenic drugs in mice on the elevated zero-maze 
Drug Strain Dosages Tested 
Open 





Anxiolytics         
alprazolam BALB/c 1 µg ICV ↑     Ring et al., 2006 
         
CDZ BALB/c 30, 56 µg ICV 56 ↑ NE    Leonard et al., 2008 
  3, 10, 30 µg ICV 30 ↑     Malberg et al., 2007 
  10 mg/kg PO ↑ ↑ ↓ ↑ ↓ Mombereau et al., 2004 
         
 C57BL/6J 5, 10, 20 mg/kg IP 20 ↓  NE NE 20 ↓ Mathiasen et al., 2008 
         
 DBA/2J 5, 10, 20 mg/kg IP NE  NE NE 20 ↓ Mathiasen et al., 2008 
         
 NMRI 5, 10, 20 mg/kg IP 5 ↑  5 ↓ 5, 10 ↑ 10, 20 ↓ Mathiasen et al., 2008 
  5, 10, 20 mg/kg IP 10, 20 ↑     Troelsen et al., 2005 
         
 OF1 10 mg/kg PO ↑ ↑ ↓ ↑ ↓ Cryan et al., 2004 
  10 mg/kg PO ↑ ↑ ↓ (NS) NE ↓ Jacobson and Cryan,  
        2008 
         
diazepam C57BL/6J 1 mg/kg IP  ↑   ↓ Bilkei-Gorzo et al., 2002 
  2 mg/kg IP ↑ ↑    Bilkei-Gorzo et al., 2004 
         
 DBA/2J 2 mg/kg IP ↑ NE    Bilkei-Gorzo et al., 2004 
         
buspirone C57BL/6J 1 mg/kg IP  NE   ↓ Bilkei-Gorzo et al., 2002 
 





Table 2. Effects of standard anxiolytic and anxiogenic drugs in mice on the elevated zero-maze 
 
Drug Strain Dosages Tested 
Open 





amitriptyline NMRI .3, 1, 3, 10 IP NE NE NE NE NE Troelsen et al., 2005 
  10 mg/kg PO 21 days NE NE NE NE NE  
         
desipramine 129SvEv X 12.5 mg/kg IP NE  NE NE NE Gur et al., 2007 
 C57BL/6        
         
citalopram NMRI 5, 10, 20,  NE NE NE NE NE Troelsen et al., 2005 
  40 mg/kg IP       
  10 mg/kg PO 21 days NE NE NE NE NE  
         
fluoxetine NMRI 1, 3, 10, 30 mg/kg IP NE NE NE NE NE Troelsen et al., 2005 
         
paroxetine NMRI 1, 3, 10, 30 mg/kg IP NE NE NE NE NE Troelsen et al., 2005 
         
duloxetine NMRI 1, 3, 10, 30 mg/kg IP NE NE 10 ↑ 10 ↑ NE Troelsen et al., 2005 
  10 mg/kg PO 21 days ↑ ↑ NE ↑ ↓  
         
venlafaxine NMRI 3, 10, 30,  NE NE NE NE NE Troelsen et al., 2005 
  60 mg/kg IP       
         
reboxetine NMRI 1, 3, 10, 30 mg/kg IP 3, 10 ↓ 1, 3 ↓ NE NE NE Troelsen et al., 2005 
  10 mg/kg PO 21 days NE NE NE NE NE  
 







Table 2. Effects of standard anxiolytic and anxiogenic drugs in mice on the elevated zero-maze. 
 
Drug Strain Dosages Tested 
Open 





Anxiogenics         
mCPP C57BL/6J .5 mg/kg IP NE NE ↑   Bilkei-Gorzo et al., 2004 
         
 DBA/2J .5 mg/kg IP ↓ ↓ NE   Bilkei-Gorzo et al., 2004 
 
All effects refer to acute administration unless otherwise noted. For the behavioral measures (open time, activity [ACT], latency 
[LAT], head dip, and stretch attend), doses producing observed effect are reported where the effect was dose dependent. Blank cells 
indicate that the measure was not reported by the authors. Open time refers to time spent in open quadrants of the maze (percentage or 
actual as reported by authors). Activity (ACT) refers to locomotor activity in the maze as reported by authors. Latency (LAT) refers to 
latency to first enter an open quadrant of the maze. Head dip refers to observations of the animal dipping its head over the edge of the 
open quadrants of the maze. Stretch attend refers to observations of animals adopting a stretched-attend posture, typically defined as 
an elongated posture with the snout stretched forward. CDZ = cholrdiazepoxide, mCPP = m-chlorophenyl-piperazine, ICV = 
intracerebroventricular injection, IP = intraperitoneal injection, PO = per os administration, ↑ = increase in measure, ↓ = decrease in 




 Noting these limitations, two experiments were performed using B6 and D2 mice. 
The B6 and D2 strains were selected as they are among the most widely available and 
thoroughly phenotyped, making them excellent reference populations. Additionally, these 
strains have been shown to differ in baseline behavior on measures thought to reflect 
aspects of depression (Alcaro et al., 2002; Crowley et al., 2005) and anxiety (Cook et al., 
2001; Wahlsten et al.; 2003), as well as in response to treatment with antidepressant 
agents (Liu et al., 2001; Lucki et al., 2001; Crowley et al., 2005).  
 Experiment 1. At the conception of this experiment, the effects of CDZ in mice on 
the EZM had only been reported in the outbred mouse strains, OF1 (Cryan et al., 2004) 
and NMRI (Troelsen et al., 2005), and the inbred strain, BALB/c (Mombereau et al., 
2004; Malberg et al., 2007). Thus, we thought that it would be beneficial to examine the 
effects of CDZ in B6 and D2 mice. Since that time, Mathiasen et al. (2008) have reported 
on the effects of CDZ in these strains on the EZM. However, there are some peculiarities 
to their observations. First, it is notable that, at baseline, B6 mice displayed greater 
anxiety-like behavior than D2 mice, which is contrary to strain differences reported in 
most studies (e.g., Tarantino et al., 2000; Tang et al., 2002; Milner and Crabbe, 2008). 
Second, the only effect of CDZ on anxiety behavior observed was an anxiogenic effect in 
B6 mice at the 20 mg/kg dose. Therefore, to clarify and extend the available data, the 
acute effects of three doses of CDZ (2.5, 5, and 7.5 mg/kg) were examined in the EZM. 
Considering the report of Mathiasen (2008), it was difficult to predict the direction of the 
effect, if any, that CDZ would have had here. However, in view of the typical effects of 




 Experiment 2. In addition to the limited characterization of the effects of 
antidepressants in the EZM, many of such studies have excluded key aspects of the 
clinical manifestations of these disorders. For example, the prevalence of anxiety and 
depressive disorders is far greater in women than in men (Anisman and Matheson, 2005; 
Toufexis et al., 2006), there is evidence of sex differences in serotonin transmission 
(Bagdy, 1998; Jones and Lucki, 2005), and differences in therapeutic efficacy of 
antidepressants (Jones and Lucki, 2005; Duman et al., 2006). However, the majority of 
animal research on the behavioral effects of antidepressants has not included females 
(Palanza, 2001; Cryan and Mombereau, 2004; Dulawa and Hen, 2005). While female 
subjects have been generally left out due to increased complexity and cost associated 
with their inclusion, those studies that have made use of female animals have reported 
sex differences in baseline behavior (Cryan and Mombereau, 2004), serotonin 
transmission (Jones et al., 1996), and behavioral responses to treatment with 
antidepressant agents (David et al., 2001; Monleón et al., 2002; Caldarone et al., 2003; 
Leuner et al., 2004; Lifschytz et al., 2006) suggesting that the inclusion of females may 
provide insight into gender disparities in anxiety-related disorders.  
 Similarly, the majority of patients experience a 2 – 3 week lag between the onset 
of antidepressant use and any therapeutic effects. Yet, most preclinical studies of 
antidepressant drugs have only examined the effects of acute administration, and 
relatively few behavioral models of depression or anxiety have been responsive to 
chronic administration of antidepressants (Brocco et al., 2002; Dulawa and Hen, 2005; 
Malberg and Blendy, 2005). This fact presents a number of problems. Foremost, the 




appears to be a central feature of these drugs in clinical populations (i.e., efficacy only 
after prolonged administration [Dulawa et al., 2004; Mitchell and Redfern, 2005]). While 
an animal model is not expected to incorporate every feature of complex disorders such 
as anxiety and depression, extending the use of commonly employed models to include 
simple, but commonly neglected, variables could increase our understanding of these 
disorders and their treatment. 
 During the early 1990‟s the „third generation‟ antidepressants were approved for 
the treatment of depression in the U.S., and within a decade, these medications accounted 
for a considerable proportion of antidepressant drugs prescribed (Hansen et al., 2010; 
Vlahiotis et al., 2011). Among these are the serotonin norepinephrine reuptake inhibitors 
(SNRIs), which act similarly to the tricyclic antidepressants in that they inhibit both 
serotonin and norepinephrine reuptake but have a more favorable side effect profile due 
to their greater specificity (Olver et al., 2001). SNRIX was one of the first SNRIs 
approved for use and its clinical efficacy in the treatment of depression and anxiety is 
well established (Kent, 2000). However, behavioral studies of SNRIX in mice are 
relatively limited, and only the acute effects of SNRIX have been examined in the EZM 
(Troelsen et al., 2005).  
 Seeking to address this, we treated male and female B6 and D2 mice with SNRIX 
or vehicle for 29 days and then measured behavior on a battery of seven tests. Our 
primary interest was the effects of chronic administration of SNRIX on behavior in the 
EZM. Therefore, behavior on the EZM was measured on the 30
th
 day following the 
initiation of drug treatment. Additionally, noting the general lack of behavioral data on 




three days. The testing battery used has previously been shown to be an effective high 
throughput behavioral screen in a large scale mutagenesis project (Cook et al., 2007) and 
allows for a timely survey of a broad range of behaviors. Thus, we hypothesized that this 
experimental design would allow us to efficiently detect strain and/ or sex dependent 
effects of chronic antidepressant administration if they did exist, while enhancing the 
range of available data on the behavioral effects of SNRIX. 
Behavioral Characterization of Adolescent Mice 
 With the major physiological, cognitive, and social changes characteristic of 
adolescence, comes an increased occurrence of impulsivity, risk-taking behavior, and 
psychopathology.  For example, in the U.S., 50% of adolescents have consumed alcohol 
and over 30% have used an illicit drug by about age 15 (Johnston et al., 2008). 
Additionally, the initial onset of generalized anxiety disorder, panic disorder, and 
obsessive compulsive disorder frequently occurs during this time (Lesch, 2001; Grover et 
al., 2005; Gregory et al., 2008). In fact, symptoms of depression and/ or anxiety are the 
leading reasons for mental health treatment among adolescents, and suicide is the third 
leading cause of death among children 15 – 19 years of age (HRSA, 2004). 
 While there is evidence that the common emergence of mood disorders during 
adolescence is related to the physical maturation of the brain (for example see: Casey et 
al., 2010), it is also clear that these developmental processes are taking place within the 
larger gene X environment interactions that shape both healthy and pathological 
outcomes (Leonardo and Hen, 2008; Casey et al., 2010). Hence, it has been proposed that 
the gene X environment interactions thought to underlie the etiology of the mood 




interactions (Leonardo and Hen, 2008). In attempting to understand these three-way 
interactions, murine models provide convenient means to examine the effects of genetic 
and environmental factors; however, the available data on baseline behavioral differences 
among juvenile mice is relatively sparse. Further, the data that is available primarily 
comes from pharmacological studies examining a wide range of ages, and often baseline 
age-related differences are not reported or age groups are analyzed separately.   
 Noting the limited research in this area, Hefner and Holmes (2007) examined 
behavior of male B6 mice at 4, 6, and 8 weeks of age which map onto what has been 
termed periadolescence (weaning to approximately 1 week prior to puberty), mid-
adolescence, and late-adolescence, respectively (Adriani et al., 2004). They used three 
measures of anxiety-related behavior (fear conditioning, EPM, and open field) and a 
measure of depression-like behavior (the forced swim test). They found age-related 
differences in fear conditioning, anxiety-like behavior in the open field, and depression-
like behavior in the forced swim test but no differences in anxiety-like behavior in the 
EPM. Considering that they found age-related differences in some, but not all, anxiety-
related measures and the possibility that age-related differences could vary with 
genotype, we sought to extend this inquiry to include additional measures and an 
additional inbred strain. Therefore, the behavior of male B6 and D2 mice beginning at 
PND 28, 42, and 56 was examined in a modified version of the testing battery used in 
Experiment 2 above. 
 Experiment 3. The choice of B6 and D2 mice was based on the characteristics 
noted previously (Vide Supra). The behavioral battery used was the same as that in 




to be tested in a single week. Given that Hefner and Holmes (2007) found the effects of 
age to be task specific, we expected that this battery would help clarify the nature of these 
differences as it provides two additional tests of anxiety-like behavior and a different test 
of depressive-like behavior.  
Method 
Subjects 
 B6 and D2 mice (35 to 40 days of age for Experiments 1 and 2; 21, 35, and 49 
days of age for Experiment 3) were purchased from the Jackson Laboratory (Bar Harbor, 
MN, USA), and housed five per cage in the University of Memphis vivarium. All animals 
had access to food and water ad libitum and were maintained on a 12:12 light/dark cycle 
with lights on at 06:30 and lights off at 18:30. The average temperature in the vivarium, 
to date, is 23
º
 C with humidity varying between 30 and 70%. The number of animals used 
in Experiments 1 and 2 are reported in Tables 3 and 4, respectively. A total of 60 mice 
(10 per experimental cell) were used in Experiment 3. 
 
 
Table 3. Number of animals used (n) by strain and CDZ dose in Experiment 1 
 
Strain Saline 2.5 mg/kg 5 mg/kg 7.5 mg/kg 
C57BL/6J 15 10 10 10 
DBA/2J 10 10 10 10 
 













Table 4. Number of animals used (n) by strain, sex, and drug dose in Experiment 2 
 
 B6 D2 
Drug Treatment Male Female Male Female 
Saline 9 11 12 10 
10 mg/kg  12 11 11 12 
30 mg/kg  12 12 11 12 
 





 Experiment 1. At PND 60, mice were weighed and placed in a darkened holding 
area for at least 30 minutes. After this habituation period mice received an intraperitoneal 
(IP) injection of either CDZ (2.5, 5, or 7.5 mg/kg) or saline. Thirty minutes later they 
were tested on the EZM.  
 Experiment 2. At PND 60, animals were weighed and received an injection of 
either SNRIX (10 or 30 mg/kg IP) or saline, once daily for 29 days. At PND 90, animals 
began four days of behavioral testing. Behavioral testing was conducted in the following 
order: Day 1: elevated zero-maze; Day 2: open field and hotplate; Day 3: light/dark, 
startle, and fear conditioning training; Day 4: testing of contextual and cued conditioning, 
and tail suspension.  
 Experiment 3. Animals were allowed one week to habituate to the vivarium 
before behavioral testing. At PND 28, 42, or 56 (4wk, 6wk, 8wk, respectively) animals 
began a four day battery of testing conducted in the following order: Day 1: elevated 
zero-maze; Day 2: open field and hotplate; Day 3: light/dark and fear conditioning 




 For all experiments, testing was conducted so that animals belonging to each 
experimental cell were represented throughout each testing period. All apparatus were 
cleaned with 70% isopropanol between mice and allowed to dry.  For Experiments 2 and 
3 all animals were tested using each measure in the same order and allowed a minimum 
habituation period of 30 min before each test. 
Drugs 
 CDZ was purchased from Sigma Chemicals (St. Louis, MO, USA). The chosen 
doses are largely based on those previously shown to have an anxiolytic effect in mice on 
the EPM (Lister et al., 1987; Raupp et al., 2008; Clément et al., 2009; Paterson et al., 
2010) but below those producing sedation (Fielding and Hoffman, 1979). SNRIX was 
provided by the pharmaceutical company holding rights to this drug. Dosages of 10 and 
30 mg/kg were chosen as approximations of both those reported in the literature to be 
behaviorally effective in mice and those shown to produce serum levels within the 
therapeutic range when administered chronically (Ahern et al., 2006.) Dosages were 
calculated as the weight of the salt. Both drugs were dissolved in .9% saline (w/v) and 
administered in an injection volume of 10 ml/kg. Control animals were injected with an 
equivalent volume of .9% saline alone. 
Behavioral Testing and Apparatus 
Elevated Zero Maze. Elevated zero mazes were manufactured by AccuScan 
Instruments (Columbus, OH, USA). The apparatus is an elevated black circular platform 
consisting of open and closed quadrants. Because we are interested in the avoidance of 
open versus closed areas and to minimize differences in light intensity between the open 




height (Martínez et al., 2002). The closed quadrants are each equipped with infrared light 
beams allowing the amount of time spent and activity in the closed quadrants to be 
monitored. The open quadrants have a slightly raised Plexiglas lip to prevent the mice 
from falling off of the maze. The zero-maze has been described in detail elsewhere (Cook 
et al., 2001). 
Mazes were separated from one another by solid partitions such that each maze is 
equidistant from three extra-maze walls. A greater range of behavior is generally 
displayed when testing is performed under dim and/or red light (Kalinichev et al., 2002; 
Tang et al., 2002). Therefore, like others (Parfitt et al., 2007), each maze was dimly lit by 
a 15W red light bulb suspended approximately 125 cm above the maze, providing an 
average illumination of 14 lx at the level of each quadrant. 
 On the day of testing, animals were acclimated to a darkened holding area prior to 
testing. Test duration was five minutes. Animals were placed in a closed quadrant to 
begin the test period. Latency to enter an open quadrant, total time spent in open and 
closed quadrants, and activity in the closed quadrants was recorded. Activity levels can 
vary greatly because their measurement is a function of time spent in the closed 
quadrants; therefore, we evaluate activity as beam breaks per second spent in the closed 
quadrants.  
Open Field. The open field arenas consist of a Plexiglas open field insert (24.13 
cm x 45.72 cm) in a HamiltonKinder SmartFrameTM system (HamiltonKinder, Poway,CA, 
USA).  The system uses two 4x8 photobeam arrays, one to detect horizontal movements 




Animals were placed in the center of the open field to begin the 20 min test 
period. Based on the position and sequence of beam breaks during the test period the 
following measures were evaluated: distance traveled , rears, and percentage of time 
spent in the center of the arena (defined as the 9 x 10 cm area located 15 cm from front 
and back walls and 4.5 cm from the left and right walls of the arena), percentage of time 
spent in the corners of the arena, percentage of total distance traveled occurring in the 
center of the arena, and habituation ratio (i.e. the ratio of distance traveled during the last 
five minutes of testing to the sum of the distance traveled during the first and last five 
minutes of testing.) At the end of the testing period animals were returned to their home 
cage until the next test.  
Hotplate. A hotplate algesia meter (Model 39) manufactured by IITC Inc. 
(Woodland Hills, CA, USA) was used. The unit has an anodized aluminum plate 
measuring 27.94 X 26.67 X 1.91 cm.  A heat sink compound (Radio Shack® Cat no. 273-
1372) was used between the hotplate surface and the aluminum plate to facilitate an even 
distribution of heat. The aluminum plate was held in position with binder clips.  A small, 
bottomless translucent grey Plexiglas enclosure (8.5 X 6.5 X 8.5 cm) was used to confine 
animals to the center of the aluminum plate. 
All overhead lights were turned off 30 minutes prior to testing. A small desk lamp 
directed away from the algesia meter and a mirror placed behind the hotplate was used to 
facilitate observations of the animal. The hotplate was heated to 52° C, and a surface 
thermometer was used to verify the temperature throughout the test. The mouse was 
placed in the Plexiglas enclosure in the center of the hotplate and observed for pain 




a pain response was displayed, the animal was immediately removed from the hotplate 
and the latency recorded.   If the animal did not show a pain response within 20 seconds, 
it was immediately removed and the test discontinued. For those animals that did not 
respond, the maximum latency of 20 seconds was assigned.  
Light-Dark. The light dark apparatus is identical to the apparatus used for open 
field only different inserts are used. The light/dark inserts are of the same overall 
dimensions, except that one half is made of clear Plexiglas and the other half is made 
black Plexiglas. The two halves are separated by a manual guillotine door that allows the 
animal to move freely between the two compartments when removed. The light half of 
the light/dark enclosure is illuminated by a 15 W light bulb approximately 48 cm above 
the chamber providing an average illumination of 33 lx in the light half and 1 lx in the 
dark half of the apparatus. 
 Overhead lights were turned off thirty minutes prior to testing. To begin the 10 
minute test period, animals were placed in the light half of the box and the guillotine door 
was then removed. The distance traveled in the either side of the box, percentage of time 
spent in the light side of the apparatus, and the percentage of the total distance traveled 
that occurred in the light side were measured. At the end of the test period animals were 
returned to their home cages. 
 Acoustic Startle/Prepulse Inhibition. A HamiltonKinder SM100 Startle Monitor 
was used. The system consists of base plate, mouse sensing plate, mouse restrainer, and 
Newton impulse Calibrator (calibrated in newtons) enclosed in a sound attenuating 




The system is designed to provide +/- 1 db accuracy on a scale from 57-120 db and to 
minimize variability between test chambers (<1 db; www.hamiltonkinder.com.) 
 Animals were placed in the startle chamber with a 65 db background white noise 
and allowed to habituate for two minutes.  The two minute period was followed by 55 
pseudo-random trials separated by 15 second intertrial intervals.  A 120 db white noise 
burst was used as the acoustic startle stimulus.  Pre-pulses were 70, 80, and 85 db white 
noise bursts lasting 20 ms which precede the startle stimulus by 100 ms. Startle response 
to the startle stimulus and to each of the pre-pulse db levels was measured. Pre-pulse 
inhibition was calculated using the following formula [100- (pre-pulse startle/acoustic 
startle) x 100]. Animals were returned to their home cage following testing. 
 Fear Conditioning. The Hamilton-Kindler SmartFrame system was used in 
conjunction with fear conditioning inserts (24.13 cm x 22.86 cm). The inserts have a grid 
floor connected to a shock generator and the top of the box includes a speaker attached to 
a sound generator.  
 Training. Animals were placed in the fear conditioning chambers and allowed to 
habituate for 2.5 minutes.  Animals were then presented with three pairings of an 85 db 
tone and a 0.36 mA foot shock separated by a 2.5 minute intertrial interval.  The tone was 
presented for 30 seconds and the shock was administered during the last 2 seconds of the 
tone. Because this test is automated, beam breaks were measured in 30 second intervals. 
The average number of beam breaks per 30 second interval for the first two minutes of 
training was used as an indication of baseline activity. The ratio of baseline activity to the 




pairing (suppression of activity by training) was used as an indicator of the degree to 
which the training procedure suppressed activity.  
 Contextual Conditioning. On the day following the training session, animals were 
placed back into the same chambers where they underwent training. During this 6 minute 
session, activity (beam breaks) per 30 second bin was measured and compared to activity 
during the habituation period on the training day.  The ratio of baseline activity to activity 
during re-exposure to the training context was used as a measure of conditioning to the 
context.   
 Cued Conditioning. Approximately 2 hr later, behavior was tested in an altered 
context.  The fear conditioning chambers were altered by placing a plastic grey tile over 
the grid floor, placing a black Plexiglas insert over the walls of the chambers, and 
attaching a small cup containing orange oil diluted in water in the upper corner of the 
box.  Animals were allowed to explore the altered environment for 2.5 minutes, after 
which time, the conditioned stimulus (tone) was presented for 2.5 minutes. Activity 
(beam breaks) was measured in 30 second bins. Activity suppression during presentation 
of the tone was evaluated relative to activity during the habituation period in the altered 
context. Animals were returned to their home cage following each session. 
 Tail suspension. A tail suspension apparatus manufactured by MedAssociates 
(St. Albans, VT, USA) was used. Each unit consists of a linear load cell with an amplifier 
and filter connected to a transducer. The units are each enclosed by an open faced 
cubicle.  
 All animals were weighed to the nearest .1 g prior to tail suspension testing. The 




calculates a threshold for force of movement for each animal.  At the start of the session 
each animal‟s tail was taped to the transducer. Force of movement was recorded for six 
minutes. The session was divided into twelve 30 second intervals, and time spent above 
threshold was examined for the entire session and each interval. Animals were observed 
during testing and tail climbing recorded. Those animals that climbed their tails were not 
included in the analysis.  
Analysis 
 Experiment 1. Data for the dependent variables were examined using analysis of 
variance (ANOVA) with strain and CDZ dose as between subjects variables. 
Experiment 2. Data from the light/ dark box and tail suspension test were lost 
during the experiment for some animals due to a computer error. The number of animals 
missing and the treatment groups to which they belonged is reported along with the 
results from these tests. Prior to the analysis of data from these tests, all observations 
were coded dichotomously as missing or not. This was then compared to all other 
variables in the study via bivariate correlation in order to determine the nature of the 
missing data. Significant correlations between missing observations and other variables 
are reported along with the results. 
 Three-way ANOVA using strain, sex, and drug dosage as the between subjects 
variables for each independent measure were used to analyze the data. The only 
exceptions to this were the analyses of body weight, interval data from the tail suspension 
test, and tail climbing behavior. For body weight and tail suspension intervals repeated 
measures ANOVA were performed using strain, sex, and drug dosage as between subject 




climbing during the tail suspension test were coded dichotomously and analyzed using 
logistic regression analysis with the independent variables strain, sex, and drug dosage as 
predictors. 
 Experiment 3. Data were analyzed using separate two-way ANOVAs for each 
dependent measure with strain and age as between subject factors. Again here, tail 
suspension interval data were analyzed using a repeated measures ANOVA. 
For all analyses, where significant effects were found (p < .05), post hoc 
comparisons were made using Tukey‟s HSD method or analysis of simple effects was 
employed, as appropriate. Effect sizes are presented for select variables in the discussion 
to aid in the interpretation of the results. All analyses and calculations were performed 




 Upon inspection of the data, we found that some animals‟ measures on latency to 
enter an open quadrant and percentage of time in the open quadrants of the maze were 
extreme. Two animals‟ latency measures were more than three standard deviations from 
the mean (one B6 mouse in the 2.5 mg/kg group and one D2 mouse in the saline group), 
and four animals scored more than three standard deviations from the mean on the 
percentage of time spent in the open quadrants (one B6 mouse given 2.5 mg/kg, one D2 
mouse given 2.5 mg/kg, and two D2 mice in the 7.5 mg/kg group). Therefore, these 
animals were considered to be outliers and were not included in the respective analyses. 




 Activity in the closed quadrants. ANOVA revealed a significant effect of strain 
on activity, F (1, 77) = 3.928, p = .05, with B6 mice being slightly more active than D2 
mice (M = 2.54, SD = .41 and M = 2.36, SD = .42, respectively). ANOVA failed to 
detect an effect of CDZ or an interaction between strain and CDZ administration, F (3, 
77) = 2.033, p = .116, and F (3, 77) = .919, p = .436, respectively. 
 
Table 5. Means and standard errors of measures in the elevated zero maze for 
Experiment 1 by strain and drug treatment  
 
 Saline 2.5 mg/kg 5 mg/kg 7.5 mg/kg 
Strain Activity 
B6 2.59 (.11) 2.28 (.13) 2.77 (.13) 2.53 (.13) 
D2 2.32 (.13) 2.27 (.13) 2.40 (.13) 2.47 (.13) 
 Latency (s) to Enter an Open Quadrant 
B6 5.97 (2.77) 10.46 (3.57) 4.64 (3.39) 3.05 (3.39) 
D2 12.30 (3.57) 15.78 (3.39) 13.50 (3.39) 20.90 (3.39) 
 Percentage of Time Spent in the Open Quadrants 
B6 24.91 (2.68) 20.12 (3.46) 18.12 (3.28) 29.47 (3.66) 
D2 12.10 (3.28) 15.40 (3.46) 10.18 (3.28) 24.11 (3.66) 
  
Animals were administered saline, 2.5, 5, or 7.5 mg/kg chlordiazepoxide thirty minutes 
prior to testing. Numbers are means and numbers in parentheses are standard errors of the 
means. Activity is measured as beam breaks per second spent in the closed quadrants of 
the maze. B6 = C57BL/6J, D2 = DBA/2J 
 
 
 Latency to first enter an open quadrant. ANOVA detected a significant effect 
of strain, F (1, 75) = 15.55, p < .001, with B6 mice exhibiting a shorter latency than D2 
mice. However, there was no effect of CDZ and no strain by drug treatment interaction, F 
(3, 75) = .678, p = .568, and F (3, 75) = 1.233, p = .304, respectively. 
 Percentage of time spent in the open quadrants. ANOVA revealed a significant 




quadrants than D2 mice. Likewise, a significant effect of CDZ was found, F (3, 73) = 
4.911, p = .004. See Figure 1, panel A. Post hoc testing indicated that none of the doses 
tested differed from saline alone, but animals administered 7.5 mg/kg CDZ spent more 
time in the open quadrants of the maze than those given either 2.5 or 5 mg/kg. Examining 
the means by strain suggests that the effect of CDZ is largely driven by an effect of 7.5 
mg/kg increasing time spent in the open in D2 but not B6 mice. See Figure 1, panel B. 
However, the strain by drug treatment interaction was not significant, F (3, 73) = .677, p 
= .569. None the less, if the data are analyzed separately by strain an effect of CDZ is 
found in D2 mice but not B6 mice (D2 mice: F (3, 33) = 3.44, p = .028; B6 mice: F (3, 





Figure 1. Effects of CDZ on the percentage of time spent in the open quadrants of the 
elevated zero maze. Data are presented as means ± SEM. A.) Main effect of drug dose. 
Groups that do not share a common lower case letter are significantly different at the 
level p < .05. B.) The effect of CDZ by dose and strain. The interaction was non-




 To determine if drug administration affected animals‟ body weight, weights 




suspension testing on the final day of testing (PND 93) were selected for analysis. 
Repeated measures ANOVA did not detect any effects of the drug treatment on body 
weight (p > .2 for all; Data not presented) 
Elevated Zero Maze 
 Activity in the closed quadrants. ANOVA revealed a significant main effect of 
strain, F (1, 123) = 6.117, p < .05, with B6 mice being more active than D2 mice. 
ANOVA failed to detect significant main effects of sex or drug treatment: F (1, 123) = 
.045, p = .83, and F (2, 123) = .653, p = .52, respectively. Likewise, ANOVA failed to 
detect significant strain x sex, strain x drug treatment, sex x drug treatment, or strain x 
sex x drug treatment interactions: F (1, 123) = 1.173, p = .281; F (2, 123) = .829, p = .44; 
F (2, 123) = 1.292, p = .279; and F (2, 123) = .393, p = .68; respectively. (See Table 6 for 
data.) 
 Latency to enter an open quadrant. ANOVA revealed a significant main effect 
of strain, F (1, 123) = 10.016, p = .002, with B6 mice entering an open quadrant sooner 
than D2 mice (M = 4.84, SEM = 1.31, and M = 10.69, SEM = 1.30, respectively). 
However, ANOVA failed to detect an effect of sex or drug treatment: F (1, 123) = 050, p 
= .82, and F (2, 123) = 1.832, p = .16, respectively. ANOVA revealed a significant strain 
x sex interaction, F (1, 123) = 3.953, p = .049. Analysis of simple effects found no 
difference between D2 males and females, but B6 females displayed a shorter latency 
than B6 males. B6 and D2 males did not differ, but B6 females displayed a shorter 
latency than did D2 females. ANOVA did not detect significant strain x drug treatment, 




.127; F (2, 123) = .202, p = .82; and F (2, 123) = .422, p = .66; respectively. (See Table 6 
for data.) 
 
Table 6. Means and standard errors of measures in the elevated zero maze for 
Experiment 2 by strain, sex, and drug treatment 
 
 B6 D2 
Drug Treatment Male Female Male Female 
 Activity 
Saline 2.22 (.17) 2.22 (.16) 1.99 (.15) 2.01 (.16) 
10 mg/kg  2.04 (.15) 2.08 (.16) 2.14 (.16) 1.81 (.15) 
30 mg/kg  2.16 (.15) 2.46 (.15) 1.91 (.16) 2.00 (.15) 
     
 Latency (s) to Enter an Open Quadrant 
Saline 6.66 (3.57) 2.72 (3.23) 11.84 (3.09) 19.93 (3.38) 
10 mg/kg  6.68 (3.09) 4.64 (3.23) 7.03 (3.23) 8.77 (3.09) 
30 mg/kg  6.07 (3.09) 2.26 (3.09) 7.06 (3.23) 9.50 (3.39) 
     
 Percentage of Time Spent in the Open Quadrants 
Saline 16.80 (3.14) 15.88 (2.84) 11.62 (2.72) 15.09 (2.98) 
10 mg/kg  19.57 (2.72) 19.22 (2.84) 16.68 (2.84) 16.24 (2.72) 
30 mg/kg  16.13 (2.72) 23.09 (2.72) 9.11 (2.84) 9.06 (2.72) 
 
Activity is measured as beam breaks per second spent in the closed quadrants. Numbers 
in parentheses are standard errors. B6 = C57Bl/6J, D2 = DBA/2J. 
 
 
 Percentage of time spent in an open quadrant. ANOVA revealed a main effect 
of strain, F (1, 123) = 11.335, p = .001, with B6 animals spending a greater percentage of 
time in the open quadrants of the maze. ANOVA failed to detect significant effects of sex 
or drug treatment, F (1, 123) = .786, p = .38, and F (2, 123) = 1.935, p = .149, 
respectively. Likewise, none of the interactions were found to be significant: strain x sex, 




drug treatment, F (2, 123) = .490, p = .61; strain x sex x drug treatment, F (2, 123) = 
1.35, p = .36. (See Table 6 for data.) 
Open Field 
 Total distance traveled. ANOVA revealed a significant main effect of strain, F 
(1, 123) = 30.006, p < .001, with B6 mice traveling a greater distance than D2 mice. 
Likewise, ANOVA revealed a significant effect of sex, F (1, 123) = 6.411, p = .013, with 
males traveling a greater distance than females. ANOVA failed to detect a significant 
main effect of drug treatment, F (2, 123) = .704, p = .497. However, a significant strain x 
sex interaction was found, F (1, 123) = 18.059, p < .001. Analysis of simple effects 
revealed that B6 males and females did not differ, but D2 males traveled a greater 
distance than D2 females. Further, while B6 females traveled a greater distance than D2 
females, B6 and D2 males did not differ. ANOVA failed to detect significant strain x 
drug treatment, sex x drug treatment, or strain x sex x drug treatment interactions: F (2, 
123) = .413, p = .66; F (2, 123) = .596, p = .55; and F (2, 123) = .623, p = .54; 
respectively. (See Table 7 for data.) 
 Rears. ANOVA failed to detect significant main effects of strain, sex, or drug 
treatment: F (1, 123) = 1.537, p = .212; F (1, 123) = .206, p = .65; and F (2, 123) = .653, 
p = .52; respectively. However, a significant strain x sex interaction was found, F (1, 123) 
= 11.756, p = .001. Analysis of simple effects revealed that B6 females reared more 
frequently than B6 males, but D2 males reared more frequently than D2 females. 
Likewise, D2 males reared more frequently than B6 males, and B6 females reared more 




 sex x drug treatment, or strain x sex x drug treatment interactions: F (2, 123) = .204, p = 
.82; F (2, 123) = .156, p = .86; and F (2, 123) = 1.557, p = .22; respectively. (See Table 7 
for data.) 
 
Table 7. Means and standard errors for measures in the open field in Experiment 2 
by strain, sex, and drug treatment 
 
 B6 D2 
Drug Treatment Male Female Male Female 
 Total Distance (cm) Traveled 
Saline 2031.1 (207.7) 2155.0 (187.9) 2010.8 (179.9) 1012.9 (197.0) 
10 mg/kg  1839.0 (179.9) 2204.4 (187.9) 1648.8 (187.9) 971.8 (179.9) 
30 mg/kg  1868.5 (179.9) 1934.0 (179.9) 1682.4 (187.9) 1166.8 (179.9) 
     
 Number of rears  
Saline 106.67 (13.90) 124.00 (12.58) 125.42 (12.04) 100.40 (13.19) 
10 mg/kg  101.50 (12.04) 144.82 (12.58) 130.91 (12.58) 91.25 (12.04) 
30 mg/kg  128.42 (12.04) 132.08 (12.04) 127.27 (12.58) 108.00 (12.04) 
     
 Habituation Ratio 
Saline .442 (.029) .378 (.026) .417 (.025) .379 (.028) 
10 mg/kg  .458 (.025) .362 (.026) .451 (.026) .358 (.025) 
30 mg/kg  .409 (.025) .367 (.025) .421 (.026) .369 (.025) 
     
 Percentage of Time Spent in Corners 
Saline 42.09 (1.97) 44.89 (1.78) 38.68 (1.71) 29.22 (1.87) 
10 mg/kg  45.70 (1.71) 41.80 (1.78) 37.36 (1.78) 26.79 (1.71) 
30 mg/kg  39.90 (1.71) 43.49 (1.71) 40.09 (1.78) 26.20 (1.71) 
     
 Percentage of Distance Traveled Occurring in the Center 
Saline 39.12 (2.25) 37.77 (2.04) 26.26 (1.95) 16.95 (2.13) 
10 mg/kg  37.41 (1.95) 38.24 (2.04) 25.98 (2.04) 13.65 (1.95) 
30 mg/kg  42.08 (1.95) 34.54 (1.95) 27.90 (2.04) 19.45 (1.95) 
 
Numbers are means. Numbers in parentheses are standard errors. Habituation ratio is the 
distance traveled during the last five minutes of testing over the sum of the distance 






 Habituation Ratio. ANOVA failed to detect a main effect of strain, F (1, 123) = 
.054, p = .82. However, a significant main effect of sex was found, F (1, 123) = 18.097, p 
< .001, with males demonstrating a greater degree of habituation to the arena than 
females. ANOVA failed to detect a main effect of drug treatment, F (2, 123) = .420, p = 
.66. Likewise, no significant strain x sex, strain x drug treatment, sex x drug treatment, or 
strain x sex x drug treatment interactions were found: F (1, 123) = .043, p = .84; F (2, 
123) = .127, p = .88; F (2, 123) = 1.032, p = .36; and F (2, 123) = .114, p = .89; 
respectively. (See Table 7 for data.) 
 Percentage of time spent in the corners of the arena. ANOVA revealed a main 
effect of strain, F (1, 123) = 94.476, p < .001, with B6 mice spending a greater 
percentage of time in the corners than D2 mice. A main effect of sex was also found, F 
(1, 123) = 26.328, p < .001, with males spending a greater percentage of time in the 
corners than females. ANOVA failed to detect a significant main effect of drug treatment, 
F (1, 123) = .584, p = .58. However, a significant strain x sex interaction was found, F (1, 
123) = 35.356, p < .001. Analysis of simple effects revealed that while B6 males and 
females did not differ, D2 males spent a greater percentage of time in the corners than did 
D2 females. Further, while B6 and D2 males did not differ, B6 females spent a greater 
percentage of time in the corners than did D2 females. ANOVA failed to detect 
significant strain x drug treatment, sex x drug treatment, or strain x sex x drug treatment 
interactions: F (2, 123) = .843, p = .43; F (2, 123) = 1.197, p = .306; and F (2, 123) = 
2.430, p = .092; respectively. (See Table 7 for data.) 
 Percentage time spent in the center of the arena. ANOVA revealed a main 




percentage of time in the center of the arena than D2 mice. Likewise, a main effect of sex 
was detected, F (1, 123) = 15.924, p < .001, with males spending more time in the center 
than females. ANOVA failed to detect a main effect of drug treatment, F (2, 123) = .217, 
p = .81. A significant strain x sex interaction was found, F (1, 123) = 4.584, p = .034. 
Analysis of simple effects confirmed that B6 mice of both sexes spent more time in the 
center of the arena than did D2 mice of both sexes. Further, while there was no difference 
between B6 males and females, D2 females spent more time in the center than D2 males. 
ANOVA did not detect a significant strain x drug treatment interaction, F (2, 123) = .048, 
p = .953, but the sex x drug treatment interaction was found to be significant, F (2, 123) = 
3.475, p = .034. Analysis of simple effects found that among females the drug treatment 
had no effect. However, in males, 30 mg/kg increased the amount of time spent in the 
center of arena, but 10 mg/kg of the drug had no effect. Further, males and females given 
SAL or 10 mg/kg of the drug did not differ, but males given 30 mg/kg spent more time in 
the center than did females given the same dose. Additionally, the strain x sex x drug 
treatment interaction was found to be significant, F (2, 123) = 4.701, p = .011, see Figure 
2. Analysis of simple effects showed that under all treatment conditions B6 mice spent 
more time in the center than D2 mice. Among D2 mice, males and females did not differ, 
and there was no effect of drug treatment. Among B6 mice administered either saline or 
10 mg/kg of the drug, there were no differences between drug treatments or sexes. 
However, B6 males administered 30 mg/kg of the drug spent more time in the center than 
B6 males administered SAL or 10 mg/kg of the drug, but an opposite relation was seen 
among B6 females. Those given SAL or 10 mg/kg of the drug did not differ, but those 





Figure 2. The effect of SNRIX on percentage of time spent in the center of the open field 
arena by strain, sex, and dose. Data are presented as means ± SEM. Groups that do not 




 Percentage of total distance traveled occurring in the center of the arena. 
ANOVA revealed a main effect of strain, F (1, 123) = 200.182, p < .001, with B6 mice 
traveling a greater distance in the center than D2 mice. Additionally, the main effect of 
sex was significant, F (1, 123) = 29.729, p < .001, with males traveling a greater distance 
in the center of the arena than females. ANOVA failed to detect a main effect of drug 
treatment, F (2, 123) = 1.203, p = .304. A significant strain by sex interaction was found, 
F (1, 123) = 9.916, p = .002. Analysis of simple effects revealed that both B6 males and 
females traveled a greater distance in the center than did their respective D2 counterparts. 




the center than did D2 females. ANOVA failed to detect significant strain x drug 
treatment or sex x drug treatment interactions: F (2, 123) = .750, p = .47, and F (2, 123) = 
.510, p = .60, respectively. Likewise, the strain x sex x drug treatment interaction failed 
to reach significance, F (2, 123) = 2.411, p = .094. (See Table 7 for data.) 
Hotplate 
 Latency to display hindpaw pain response. ANOVA revealed a main effect of 
strain, F (1, 123) = 16.980, p < .001, with B6 mice showing a pain response sooner than 
D2 mice. ANOVA failed to detect a main effect of sex or drug treatment: F (1, 123) = 
1.306, p = .255, and F (2, 123) = 1.068, p = .347, respectively. Likewise, ANOVA failed 
to detect a significant strain x sex, strain x drug treatment, sex x drug treatment, or strain 
x sex x drug treatment interaction: F (1, 123) = .261, p = .611; F (2, 123) = .292, p = 
.747; F (2, 123) = 1.152, p = .320; and F (2, 123) = 1.158, p = .318; respectively. (See 
Table 8 for data.) 
 
Table 8. Mean latency (s) to display a pain response in the hotplate algesia test in 
Experiment 2 by strain, sex, and drug treatment  
 
 B6 D2 
Drug Treatment Male Female Male Female 
Saline 15.28 (1.58) 15.50 (1.43) 17.67 (1.37) 19.73 (1.50) 
10 mg/kg  12.29 (1.37) 14.70 (1.43) 16.54 (1.43) 18.75 (1.37) 
30 mg/kg  14.36 (1.37) 15.78 (1.37) 19.08 (1.43) 16.36 (1.37) 
 









 Although all animals were tested in the light/ dark apparatus, a computer file was 
lost resulting in data being lost for four B6 males: two received saline, one treated with 
10 mg/kg SNRIX, and 1 treated with 30 mg/kg SNRIX. To determine the nature of the 
missing data, we examined the correlations of the missing data with all other variables 
examined in the experiment. The largest correlation was with activity in the EZM, r = 
.229, p = .039. Considering that the significant correlations found were relatively weak, 
the decision was made to proceed with the analysis despite the data not being missing at 
random. 
 Percentage of time spent in the light. ANOVA revealed a main effect of strain, 
F (1, 119) = 54.108, p < .001, with B6 mice spending a greater percentage of time in the 
light side of the apparatus. Additionally, a main effect of sex was found, F (1, 119) = 
18.595, p < .001, with males spending more time in the light than females. ANOVA 
failed to detect a significant main effect of drug treatment, F (2, 119) = 1.223, p = .298. 
However a significant strain x sex interaction was found, F (1, 119) = 4.678, p = .033. 
Analysis of simple effects revealed that B6 males and females did not differ while D2 
males spent more time in the light half of the apparatus than did D2 females. Further, B6 
males spent more time in the light than D2 males, and, likewise, B6 females spent more 
time in the light than did D2 females. ANOVA failed to detect a significant strain x drug 
treatment interaction, F (2, 119) = .831, p = .438. ANOVA failed to detect a significant 
sex x drug treatment interaction despite a trend towards significance, F (2, 119) = 2.855, 
p = .061. Likewise, although not significant, ANOVA revealed a trend towards a 




Figure 3. Further inspection suggested that 10 and 30 mg/kg SNRIX resulted in B6 males 
spending a decreased amount of time in the light side of the apparatus as compared to 
saline treated B6 males while neither dose had an effect on any other strain and sex 
combination as compared to their respective control. Further, of those animals in the 
saline condition, B6 males spent the greatest percentage of time in the light followed by 
B6 females and D2 males, which did not differ, and then D2 females. B6 males, B6 
females, and D2 males administered 10 mg/kg SNRIX did not differ whereas D2 females 
administered the same dose spent less time in the light than all three. Likewise, the same 




Figure 3. The effect of SNRIX on percentage of time spent in the light side of the light-
dark apparatus by drug, sex, and dosage. Data are presented as means ± SEM. The strain 
by sex by drug treatment interaction did not quite reach significance (F (2, 119) = 2.798, 




 Total distance traveled in the light/ dark apparatus. ANOVA revealed a 
significant main effect of strain, F (1, 119) = 4.718, p = .032, with B6 mice traveling a 
greater distance than D2 mice. However, the main effects of sex and drug treatment were 
not found to be significant, F (1, 119) = 1.911, p = .17, and F (2, 119) = .188, p = .83, 
respectively. ANOVA did find a significant strain x sex interaction, F (1, 119) = 19.280, 
p < .001. Analysis of simple effects revealed that male B6 and D2 animals did not differ, 
but female B6 animals traveled a greater distance than female D2 animals. When 
comparing male and female B6 mice, it was found that females traveled further than 
males. On the other hand, male D2 mice traveled further than female D2 mice. No other 
significant interactions were found: strain x drug treatment, F (2, 119) = .236, p = .79; 
sex x drug treatment, F (2, 119) = 1.245, p = .292; and strain x sex x drug treatment, F (2, 
119) = .669, p = .52. (See Table 9 for data.) 
 Percentage of total distance traveled occurring in the light side of the 
apparatus. ANOVA revealed a significant main effect of strain, F (1, 119) = 144.405, p 
< .001, with the percentage of distance traveled occurring in the light by B6 mice being 
greater than that of D2 mice. A significant main effect of sex was also found, F (1, 119) = 
12.714, p = .001, with the percentage of total distance traveled in the light being greater 
for males than females. ANOVA failed to detect a main effect of drug treatment, F (2, 
119) = .004, p = .996. Likewise, ANOVA did not detect significant, strain x sex, strain x 
drug treatment, sex x drug treatment, or strain x sex x drug treatment interactions: F (1, 
119) = .845, p = .36; F (2, 119) = .857, p = .427; F (2, 119) = 1.619, p = .203; and F (2, 





Table 9. Mean distance (cm) traveled and mean percentage of that distance traveled 
occurring in the light side of the light-dark apparatus by strain, sex, and drug 
treatment in Experiment 2 
 
 B6 D2 
Drug Treatment Male Female Male Female 
 Total Distance Traveled 
Saline 1006.9 (93.0) 1142.6 (74.2) 1191.3 (71.1) 813.7 (77.8) 
10 mg/kg  1008.4 (74.2) 1097.8 (74.2) 1116.7 (74.2) 839.4 (71.1) 
30 mg/kg  990.6 (74.2) 1157.6 (71.1) 987.1 (74.2) 889.4 (71.1) 
     
 Percentage of Total Distance Occurring in Light 
Saline 40.26 (2.30) 32.13 (1.84) 23.40 (1.76) 19.05 (1.93) 
10 mg/kg  35.06 (1.84) 33.99 (1.84) 25.93 (1.84) 19.38 (1.76) 
30 mg/kg  34.26 (1.84) 34.91 (1.76) 24.46 (1.84) 20.90 (1.76) 
 
Numbers in parentheses are standard errors. B6 = C57Bl/6J, D2 = DBA/2J. 
 
 
Acoustic Startle/ Prepulse Inhibition 
 Response to 120 db startle stimulus. ANOVA revealed a significant main effect 
of strain, F (1, 123) = 156.750, p < .001, with B6 mice displaying a greater response than 
D2 mice. A significant main effect of sex was found as well, F (1, 123) = 14.926, p < 
.001, with males responding more forcefully than females. ANOVA failed to detect a 
significant main effect of drug treatment, F (2, 123) = .232, p = .794. A significant strain 
x sex interaction was found, F (1, 123) = 6.883, p = .01. Analysis of simple effects 
revealed that B6 males displayed a greater startle response than did B6 females, but D2 
males and females did not differ. Additionally, the response of B6 males was greater than 
D2 males, and B6 females displayed a greater response than D2 females. ANOVA failed 
to detect significant strain x drug treatment, sex x drug treatment, or strain x sex x drug 
treatment interactions: F (2, 123) = .545, p = .581; F (2, 123) = .031, p = .969; and F (2, 




 Percentage of prepulse inhibition of the startle response at 70 db. ANOVA 
revealed a significant main effect of strain, F (1, 123) = 49.846, p < .001, with B6 mice 
displaying a greater degree of inhibition than D2 mice. ANOVA failed to detect a 
significant main effect of sex, F (1, 123) = .810, p = .37. There was a non-significant 
trend towards an effect of drug treatment, F (2, 123) = 2.832, p = .063, see Figure 4. 
Further inspection showed that while 10 mg/kg SNRIX was no different than SAL, 
animals administered 30 mg/kg SNRIX displayed a greater degree of inhibition than did 
those administered SAL. No significant interactions were found: strain x sex, F (1, 123) = 
1.780, p = .185; strain x drug treatment, F (2, 123) = .142, p = .867; sex x drug treatment, 
F (2, 123) = .013, p = .849; or strain x sex x drug treatment, F (2, 123) = .823, p = .442. 
 Percentage of prepulse inhibition of the startle response at 80 db. ANOVA 
revealed a significant main effect of strain, F (1, 123) = 158.469, p < .001, with B6 mice 
displaying a greater degree of inhibition than D2 mice. A significant main effect of sex 
was also found, F (1, 123) = 9.426, p = .003, with males showing more inhibition than 
females. Additionally, ANOVA revealed a significant main effect of drug treatment, F (2, 
123) = 4.291, p = .016. See Figure 4. Post hoc analysis indicated that animals 
administered 10 mg/kg SNRIX did not differ from control animals. However, animals 
treated with 30 mg/kg SNRIX displayed a greater degree of inhibition than either those 
treated with 10 mg/kg SNRIX or saline. ANOVA failed to detect significant strain x sex,  
strain x drug treatment, sex x drug treatment, or strain x sex x drug treatment interactions: 
F (1, 123) = 2.143, p = .146; F (2, 123) = 1.929, p = .150; F (2, 123) = .820, p = .443; and 







Figure 4. The effect of SNRIX on startle response and prepulse inhibition of the startle response. Data are presented as means ± SEM. 
SNRIX had no effect on the startle response to a 120 db white noise burst. 30 mg/kg, but not 10 mg/kg SNRIX increased inhibition of 
the startle response with the 80 db prepulse (* = p < .02 compared to saline). A similar effect was seen with the 75 db prepulse, but 





 Percentage of prepulse inhibition of the startle response at 85 db. ANOVA 
detected a significant main effect of strain, F (1, 123) = 113.078, p < .001, with B6 mice 
displaying a greater degree of inhibition than D2 mice. ANOVA failed to detect 
significant main effects of sex or drug treatment: F (1, 123) = 2.869, p = .093, and F (2, 
123) = 1.492, p = .229, respectively. Likewise, ANOVA failed to detect significant strain 
x sex, strain x drug treatment, sex x drug treatment, or strain x sex x drug treatment 
interactions: F (1, 123) = .469, p = .495; F (2, 123) = 2.369, p = .098; F (2, 123) = .448, p 
= .64; and F (2, 123) = .034, p = .967; respectively.  
Fear Conditioning 
 Training: Baseline activity. ANOVA revealed a significant main effect of strain, 
F (1, 123) = 163.795, p < .001, with B6 mice being more active than D2 mice. ANOVA 
failed to detect significant main effects of sex or drug treatment: F (1, 123) = .722, p = 
.397, and F (2, 123) = .047, p = .954, respectively. ANOVA did uncover a significant 
strain x sex interaction, F (1, 123) = 5.614, p = .019. Analysis of simple effects revealed 
that B6 females were more active than B6 males, but D2 males and females did not 
differ. Further, B6 males were more active than D2 males, and B6 females were more 
active than D2 females. ANOVA failed to detect significant strain x drug treatment, sex x 
drug treatment, or strain x sex x drug treatment interactions: F (2, 123) = .009, p = .991; 
F (2, 123) = .651, p = .523; and F (2, 123) = .061, p = .941; respectively. 
 Suppression of activity by training. ANOVA revealed a non-significant trend 
towards an effect of strain, F (1, 123) = 3.706, p = .057, with B6 mice showing a greater 
suppression of activity than D2 mice. No other effects approached significance: sex, F (1, 




= .900, p = .345; strain x drug treatment, F (2, 123) = 1.760, p = .176; sex x drug 
treatment, F (2, 123) = 1.021, p = .363; and strain x sex x drug treatment, F (2, 123) = 
.314, p = .731. (See Table 10 for data.) 
 
Table 10. Means and standard errors of fear conditioning measures in Experiment 2 
by strain, age, and sex 
 
 B6 D2 
Drug Treatment Male Female Male Female 
 Suppression of Activity by Training 
Saline .336 (.125) .282 (.113) .344 (.108) .407 (.118) 
10 mg/kg  .311 (.108) .304 (.113) .325 (.113) .321 (.108) 
30 mg/kg  .228 (.108) .297 (.108) .395 (.113) .712 (.108) 
     
 Suppression of Activity by Training Context 
Saline .336 (.060) .323 (.054) .702 (.052) .633 (.057) 
10 mg/kg  .313 (.052) .361 (.054) .795 (.054) .543 (.052) 
30 mg/kg  .352 (.052) .347 (.052) .707 (.054) .645 (.052) 
     
 Suppression of Activity by Cue 
Saline .238 (.050) .192 (.045) .258 (.043) .223 (.047) 
10 mg/kg  .220 (.043) .190 (.045) .342 (.045) .288 (.043) 
30 mg/kg  .222 (.043) .153 (.043) .217 (.045) .269 (.043) 
 
Numbers are means, and numbers in parentheses are standard errors. Suppression of 
activity by training is calculated as beam breaks during the 30 seconds following the final 
tone-shock pairing divided by the average number of beam breaks per 30 second bin 
during the first two minutes of the training session. Suppression of activity by the training 
context is calculated as the average number of beam breaks per 30 second bin during 
exposure to the training context on the second day divided by the average number of 
beam breaks per 30 second bin during the first two minutes of the training session. 
Suppression of activity by the cue is calculated as the average number of beam breaks per 
30 second bin during the first three minutes of exposure to the altered context on the 
second day divided by the average number of beam breaks per 30 second bin during the 
presentation of the tone in the altered context. (Smaller numbers indicate a greater 






 Contextual conditioning: Suppression of baseline activity by training context. 
ANOVA detected a significant main effect of strain, F (1, 123) = 114.865, p < .001, with 
B6 mice displaying less activity in the training context than D2 mice relative to their 
baseline activity during training. ANOVA failed to detect main effects of sex or drug 
treatment: F (1, 123) = 3.598, p = .06, and F (2, 123) = .070, p = .933, respectively. 
However, ANOVA revealed a significant strain x sex interaction, F (1, 123) = 4.929, p = 
.028. Analysis of simple effects revealed that B6 males and females did not differ, but D2 
males displayed a lesser suppression of activity in response to the training context than 
did D2 females. Further, D2 mice of both sexes were more active during exposure to the 
training context as compared to their baseline activity than B6 mice of the respective sex. 
ANOVA failed to detect significant strain x drug treatment, sex x drug treatment, or 
strain x sex x drug treatment interactions: F (2, 123) = .012, p = .988; F (2, 123) = .504, p 
= .605; and F (2, 123) = 1.746, p = .179, respectively. (See Table 10 for data.) 
 Cued conditioning: Activity in the altered context. ANOVA failed to detect a 
significant main effect of strain, F (1, 123) = 2.091, p = .151. However, a significant 
main effect of sex was found, F (1, 123) = 3.993, p = .048, with females showing a lower 
level of activity in the altered context than males. ANOVA failed to detect a significant 
effect of drug treatment, F (2, 123) = .758, p = .471. The strain x sex interaction was 
significant, F (1, 123) = 6.690, p = .011. Analysis of simple effects revealed that B6 
males and females did not differ, but D2 females were less active than D2 males. 
Additionally, B6 and D2 males did not differ, but D2 females were less active than B6 




treatment, or strain x sex x drug treatment interactions: F (2, 123) = .422, p = .657; F (2, 
123) = .484, p = .618; and F (2, 123) = 1.487, p = .230, respectively.  
 Cue suppression of activity in the altered context. ANOVA revealed a significant 
main effect of strain, F (1, 123) = 6.093, p = .015, with B6 mice displaying a greater 
reduction in activity during the presentation of the tone than D2 mice. ANOVA failed to 
detect significant main effects of sex or drug treatment: F (1, 123) = 1.385, p = .242, and 
F (2, 123) = 1.092, p = .339, respectively. Likewise, ANOVA failed to detect significant 
strain x sex, strain x drug treatment, sex x drug treatment, or strain x sex x drug treatment 
interactions: F (1, 123) = .488, p = .486; F (2, 123) = .917, p = .402; F (2, 123) = .193, p 
= .825; and F (2, 123) = .750, p = .475; respectively. (See Table 10 for data.) 
Tail Suspension 
 All animals were tested on tail suspension, but data from 10 mice were lost due to 
a computer error. Of those animals seven were B6 (3 males receiving 10 mg/kg SNRIX, 
1 female receiving saline, 1 female receiving 10 mg/kg SNRIX, and 2 females receiving 
30 mg/kg SNRIX) and three were D2 (1 male receiving 10 mg/kg SNRIX and 2 females 
receiving 30 mg/kg SNRIX). We examined the correlations of the missing data with all 
other variables included in the experiment to determine if the data was missing at 
random. The missing data was significantly correlated with three variables: activity 
during the final 30 s of training for fear conditioning, r = .230, p = .007; activity in the 
altered context of fear conditioning, r = .205, p = .017; and tail climbing during tail 
suspension testing, r = - .180, p = .036. Although the data can not be said to be missing at 
random, the correlations are relatively small, and the analysis was carried out on 




 Tail climbing. We observed a large number of animals that climbed their tails 
during the tail suspension procedure, 31.2 %. Data for tail climbing was recorded (coded 
dichotomously) in the experimenter‟s notes, and therefore no data was lost for this 
variable. Logistic regression analysis indicated that strain did not predict tail climbing, 
OR: .701, p = .375, 95% CI: .320 – 1.536. However, sex did predict tail climbing, OR: 
3.766, p = .001, 95% CI: 1.668 – 8.500, with males being over three times more likely to 
climb their tails than females. Drug treatment was not associated with tail climbing, p = 
.586 (10 mg/kg SNRIX versus SAL: OR: 1.104, p =.837, 95% CI: .429 – 2.838; 30 mg/kg 
SNRIX versus SAL: OR: .680, p = .442, 95% CI: .255 – 1.818). Animals that climbed 
their tail were omitted from further analysis of tail suspension data. 
 Time below threshold (immobility): Time below threshold per 30 s block of the 
six minute session. The six minute session was divided into 30 s intervals and analyzed 
via a repeated measures ANOVA using interval as a within subjects variable. Repeated 
measures ANOVA revealed a significant effect of interval, F (11, 814) = 66.132, p < 
.001. Further, inspection of the data showed that time spent below threshold did not 
change during the first two intervals. Immobility increased between the third and eighth 
interval at which point it reached a plateau. Repeated measures ANOVA revealed a 
significant interval by strain interaction, F (11, 814) = 8.466, p < .001. Inspection of the 
data showed that B6 mice initially exhibited less immobility than D2 mice. However, B6 
mice demonstrated increasing immobility at a rate greater than D2 mice resulting in B6 
mice reaching a greater level of immobility than D2 mice from interval six through ten. 
B6 and D2 mice did not differ between intervals 10 and 12. Repeated measures ANOVA 




.457;  interval x drug treatment, F (22, 814) = .953, p = .524; interval x strain x sex, F 
(11, 814) = .597, p = .832; interval x strain x drug treatment, F (22, 814) = .876, p = .627; 
interval x sex x drug treatment, F (22, 814) = .975, p = .495; or interval x strain x sex x 
drug treatment, F (22, 814) = 1.036, p = .416.  
 Overall time below threshold. ANOVA failed to detect a significant main effect 
of strain, F (1, 74) = 2.729, p = .103. A significant main effect of sex was found, F (1, 
74) = 4.089, p = .047, with females spending a greater amount of time immobile than 
males. ANOVA failed to detect a significant main effect of drug treatment, F (2, 74) = 
.361, p = .698. Likewise, ANOVA failed to detect significant strain x sex, strain x drug 
treatment, sex x drug treatment, or strain x sex x drug treatment interactions: F (1, 74) = 
.164, p = .687; F (2, 74) = 1.143, p = .324, F (2, 74) = .648, p = .526; and F (2, 74) = 
.615, p = .544; respectively. (See Table 11 for data.) 
 
Table 11. Mean time (s) spent below threshold (immobility) during the tail 
suspension test in Experiment 2 by strain, sex, and drug treatment  
 
 B6 D2 
Drug Treatment Male Female Male Female 
Saline 177.00 (23.45) 210.56 (15.64) 152.00 (17.73) 172.38 (16.58) 
10 mg/kg  209.00 (23.45) 192.10 (14.83) 162.80 (20.98) 188.57 (17.73) 
30 mg/kg  159.17 (19.15) 194.00 (14.83) 164.89 (15.64) 196.00 (17.73) 
 
Animals that climbed their tails were not included in the analysis. Numbers in 










Elevated Zero Maze 
 Activity in the closed quadrants. ANOVA found a significant effect of strain, F 
(1, 54) = 18.004, p < .001, with B6 mice being more active than D2 mice. Likewise, the 
effect of age was significant, F (1, 54) = 3.287, p = .045. (See Figure 5.) 6wk mice were 
the most active followed by 8wk and 4wk mice. Post hoc testing showed that the 8wk 
mice were the same as 4wk or 6wk, but the 6wk mice were more active than their 4wk 
counterparts. The strain by age interaction failed to reach significance, F (2, 54) = .763, p 
= .471. (Data are presented in Table 12.) 
 Latency to enter an open quadrant. ANOVA indicated a significant effect of 
strain, F (1, 54) = 12.849, p = .001, with D2 mice showing a longer latency than B6 mice. 
However, there was no effect of age, F (2, 54) = 1.903, p = .159, and the strain by age 
interaction was non-significant, F (2, 54) = .459, p = .634. (Data are presented in Table 
12.) 
 Percentage of time spent in an open quadrant. ANOVA revealed a significant 
effect of strain, F (1, 54) = 7.067, p = .01, with B6 mice spending more time in the open 
than D2 mice. There was a trend towards a main effect of age, but this did not quite reach 
significance, F (2, 54) = 2.971, p = .060. (See Figure 5.) 8wk mice spent the least amount 
of time in the open followed by 4wk and 6wk mice, which spent the greatest amount of 
time in the open. The strain by age interaction was found to be non-significant, F (2, 54) 







Figure 5. Age-related differences in behavior in the elevated zero maze. Data are 
presented as Means ± SEM A.) Activity in the closed quadrants of the maze. Activity is 
measured as beam breaks per second spent in the closed quadrants. Groups that do not 
share a common lowercase letter are different at the level, p < .05. B.) Percentage of time 
spent in the open quadrants of the maze. The main effect of age did not quite reach 
significance (F (2, 54) = 2.971, p = .060, ES: f = .331). 4 wk = four weeks of age, 6 wk = 






Table 12. Means and standard errors of measures in the elevated zero maze by age 
and strain 
 
 4 weeks 6 weeks 8 weeks 
Strain Percentage of Time in the Open Quadrants 
B6 23.28 (3.29) 27.23 (3.29) 23.88 (3.29) 
D2 17.23 (3.29) 24.03 (3.29) 11.68 (3.29) 
    
 Activity in the Closed Quadrants 
B6 2.49 (.11) 2.63 (.11) 2.55 (.11) 
D2 1.97 (.11) 2.40 (.11) 2.14 (.11) 
    
 Latency (s) to Enter an Open Quadrant 
B6 4.09 (3.22) 5.89 (3.22) 7.29 (3.22) 
D2 10.52 (3.22) 15.15 (3.22) 19.89 (3.22) 
 
Numbers are means, and numbers in parentheses are standard errors. Activity is measured 




 Total distance traveled. ANOVA revealed a significant effect of strain on the 
distance traveled in the open field, F (1, 54) = 22.701, p < .001, with B6 mice traveling 
further than D2 mice. The main effect of age and the strain by age interaction failed to 
reach significance, F (2, 54) = .497, p = .611, and F (2, 54) = 1.813, p = .173, 
respectively. (Data are presented in Figure 6.) 
 Rears. ANOVA found no effects of the independent variables on the number of 
rears in the open field: strain, F (1, 54) = .019, p = .892; age, F (2, 54) = .144, p = .866; 
and strain by age, F (2, 54) = 1.501, p = .232. (Data are presented in Table 13.) 
 Habituation Ratio. ANOVA indicated that the independent variables were 




F (2, 54) = 1.538, p = .224; and strain by age, F (2, 54) = 2.014, p = .143. (Data are 
presented in Table 13.) 
 Percentage of time spent in the corners of the arena. ANOVA revealed a 
significant effect of strain on time spent in the corners, F (1, 54) = 47.051, p < .001, with 
B6 mice spending more time in the corners than D2 mice. However, there was no effect 
of age, F (2, 54) = .909, p = .409, and the strain by age interaction was not significant, F 
(2, 54) = .143, p = .867. (Data are presented in Table 13.) 
 
Table 13. Means and standard errors of number of rears, habituation ratio, and 
percentage of time spent in the corners of the open field by age and strain 
 
 4 weeks 6 weeks 8 weeks 
Strain Rears 
B6 128.2 (15.53) 141.2 (15.53) 147.5 (15.53) 
D2 157.1 (15.53) 142.4 (15.53) 122.6 (15.53) 
    
 Habituation Ratio 
B6 .378 (.036) .403 (.036) .377 (.036) 
D2 .486 (.036) .382 (.036) .362 (.036) 
    
 Percentage of Time Spent in Corners of the Arena 
B6 45.99 (2.08) 44.00 (2.08) 43.51 (2.08) 
D2 34.06 (2.08) 33.60 (2.08) 30.96 (2.08) 
 
Numbers are means, and numbers in parentheses are standard errors. Habituation ratio is 
the distance traveled during the last five minutes of testing over the sum of the distance 
traveled during the first and last five minutes of testing. B6 = C57Bl/6J, D2 = DBA/2J. 
 
 
 Percentage time spent in the center of the arena. ANOVA found a significant 
effect of strain, F (1, 54) = 74.792, p < .001, with B6 mice spending more time in the 
center of the arena than D2 mice. The effect of age did not reach significance, F (2, 54) = 




= .006. (See Figure 6.) Analysis of simple effects showed that at all ages B6 mice spent 
more time in the center than D2 mice. Among B6 mice, 4wk and 6wk did not differ, but 
8wk mice spent more time in the center than either of the younger age groups. On the 
other hand, there was no difference between the age groups for D2 mice. 
 Percentage of total distance traveled occurring in the center of the arena. 
ANOVA revealed a significant main effect of strain, F (1, 54) = 49.635, p < .001, with 
B6 mice traveling a greater distance in the center of the arena than D2 mice. The effect of 
age failed to reach significance, F (2, 54) = .114, p = .893, but there was a significant 
strain by age interaction, F (2, 54) = 3.729, p = .030. (See Figure 6.) Analysis of simple 
effects was not able to detect any differences by age for either strain, but confirmed that 






Figure 6. Effect of age and strain on measures in the open field. Data are presented as 
means ± SEM. A.) Total distance traveled (cm). The strain by age interaction was not 
significant and is presented only for the purpose of comparison. B.) The percentage of the 
total distance traveled that occurred in the center of the open field. C.) Percentage of time 
spent in the center of the open field. Groups that do not share a common lowercase letter 
are different at the level, p < .05. 4 wk = four weeks of age, 6 wk = six weeks of age, 8 









 Latency to display hindpaw pain response. ANOVA did not find any effects of 
the independent variables on latency to display a pain response: strain, F (1, 54) = .005, p 
= .944; age, F (2, 54) = .011, p = .989; strain by age, F (2, 54) = 1.164, p = .320. (Data 
are presented in Table 14.) 
 
Table 14. Mean latency (s) to display a pain response in the hotplate algesia test by 
age and strain 
 
Strain 4 weeks 6 weeks 8 weeks 
B6 17.75 (2.16) 17.65 (2.16) 14.70 (2.16) 
D2 16.16 (2.16) 15.70 (2.16) 18.63 (2.16) 
 
Numbers in parentheses are standard errors. B6 = C57Bl/6J, D2 = DBA/2J. 
 
Light-Dark 
 Percentage of time spent in the light. ANOVA revealed a significant effect of 
strain, F (1, 54) = 13.688, p = .001, with B6 mice spending more time in the light side of 
the apparatus. However, the effect of age and the strain by age interaction were not 
significant, F (2, 54) = 1.852, p = .167, and F (2, 54) = 1.435, p = .247, respectively. 
(Data are presented in table 15.) 
 Total distance traveled in the light-dark apparatus. ANOVA showed that 
there was a significant effect of strain, F (1, 54) = 7.267, p = .009, with B6 mice traveling 
a greater distance than D2 mice. The effect of age and the age by strain interaction were 
not significant, F (2, 54) = 1.254, p = .294, and F (2, 54) = 1.705, p = .191, respectively. 





Table 15. Means and standard errors of measures in the light-dark apparatus by 
age and strain 
 
 4 weeks 6 weeks 8 weeks 
Strain Percentage of Time Spent in the Light Side 
B6 39.86 (2.69) 37.15 (2.69) 37.63 (2.69) 
D2 32.15 (2.69) 33.35 (2.69) 24.73 (2.69) 
    
 Distance (cm) Traveled 
B6 1066.2 (76.45) 1057.7 (76.45) 1236.4 (76.45) 
D2 1044.2 (76.45) 878.6 (76.45) 932.7 (76.45) 
    
 Percentage of Distance Traveled in the Light Side 
B6 42.49 (1.9) 37.77 (1.9) 39.34 (1.9) 
D2 31.35 (1.9) 27.61 (1.9) 22.88 (1.9) 
 





 Percentage of total distance traveled occurring in the light side of the 
apparatus. ANOVA found a significant effect of strain, F (1, 54) = 65.754, p < .001, 
with B6 mice traveling a greater distance in the light than D2 mice. Likewise, the effect 
of age was significant, F (2, 54) = 5.001, p = .010. (See Figure 7.) Post hoc testing 
indicated that 6wk mice, which traveled an intermediate distance in the light, did not 
differ from those 8wk or 4wk. On the other hand, the 4wk mice traveled a greater 
distance in the light than did the 8wk mice. ANOVA indicated that the stain by age 














Figure 7. Age-related differences in measures in the light-dark apparatus. Data are 
presented as means ± SEM. A.) Total distance traveled in the light-dark apparatus. The 
effect of age was not significant and is presented for the purpose of comparison. B.) 
Percentage of the total distance traveled occurring in the light side of the apparatus. 
Groups that do not share a common letter are different at the level, p < .05. C.) 
Percentage of time spent in the light side of the apparatus. The effect of age was not 
significant and is presented for the purpose of comparison. 4 wk = four weeks of age, 6 







 Training: Baseline activity. ANOVA found a significant effect of strain on 
baseline activity, F (1, 54) = 34.488, p < .001, with B6 mice being more active than D2 
mice. However, the main effect of age and the strain by age interaction were not 
significant, F (2, 54) = .205, p = .815, and F (2, 54) = .916, p = .406, respectively. 
Suppression of activity by training. ANOVA did not find the independent variables to 
have an effect on the suppression of activity by training: strain, F (1, 54) = .236, p = .629; 
age, F (2, 54) = .447, p = .642; and age by strain, F (2, 54) = 1.012, p = .370. However, 
the data did indicate that the training was successful with all animals displaying a 
reduction in activity following the final shock-tone pairing (M = .378, SEM = .035). 
 Contextual conditioning: Suppression of baseline activity by training context. 
ANOVA indicated that B6 mice showed a greater reduction of activity upon exposure to 
the training context the following day than did D2 mice, F (1, 54) = 14.400, p < .001. 
However, the main effect of age and the strain by age interaction were not significant, F 
(1, 54) = .540, p = .586, and F (2, 54) = .906, p = .410, respectively. 
 Cued conditioning: Activity in the altered context. ANOVA found that B6 mice 
were more active at baseline in the altered context than D2 mice, F (1, 54) = 7.245, p = 
.009, but there was no effect of age, F (2, 54) = .227, p = .798. Likewise, the strain by age 
interaction was not significant, F (2, 54) = .180, p = .836. Cue suppression of activity in 
the altered context. ANOVA revealed that D2 mice showed a greater suppression of 
activity in the altered context in response to the tone than did B6 mice, F (1, 54) = 




not significant, F (2, 54) = 2.055, p = .138, and F (2, 54) = .425, p = .656, respectively. 
(Data are presented in Table 16.) 
 
Table 16. Means and standard errors of fear conditioning measures by age and 
strain. 
 
 4 weeks 6 weeks 8 weeks 
Strain Suppression of Activity by Training 
B6 .44 (.09) .41 (.09) .34 (.09) 
D2 .39 (.09) .26 (.09) .43 (.09) 
    
 Suppression of Activity by Training Context 
B6 .55 (.07) .56 (.07) .43 (.07) 
D2 .74 (.07) .67 (.07) .73 (.07) 
    
 Suppression of Activity by Cue 
B6 .38 (.05) .30 (.05) .40 (.05) 
D2 .14 (.05) .14 (.05) .24 (.05) 
 
Numbers are means, and numbers in parentheses are standard errors. Suppression of 
activity by training is calculated as beam breaks during the 30 seconds following the final 
tone-shock pairing divided by the average number of beam breaks per 30 second bin 
during the first two minutes of the training session. Suppression of activity by the training 
context is calculated as the average number of beam breaks per 30 second bin during 
exposure to the training context on the second day divided by the average number of 
beam breaks per 30 second bin during the first two minutes of the training session. 
Suppression of activity by the cue is calculated as the average number of beam breaks per 
30 second bin during the first three minutes of exposure to the altered context on the 
second day divided by the average number of beam breaks per 30 second bin during the 
presentation of the tone in the altered context. (Smaller numbers indicate a greater 










Tail Suspension   
 Three animals fell off the tail suspension apparatus during testing (one mouse 
from each of the following groups: B6, 6wk; D2, 4wk; and D2 6wk). These animals were 
therefore not included in the analysis. We did not observe any animals that climbed their 
tails. 
 Time below threshold (immobility): Time below threshold per 30 s block of the 
six minute session. Repeated measures ANOVA indicated that the within-subjects 
variable, interval, was significant, F (11, 561) = 58.144, p < .001, with immobility 
increasing from interval 2 – 8 and then reaching a plateau from interval 8- 12. Likewise, 
the interval by strain interaction was significant, F (11, 561) = 12.403, p < .001, but the 
interval by age interaction was not significant, F (22, 561) = 1.464, p = .080. The three-
way interaction, interval by strain by age, was found to be significant, F (22, 561) = 
1.603, p = .041. (See Figure 8.) The B6 mice exhibited a low level of immobility during 
the first two intervals of testing followed by a sharp increase in immobility between 
intervals two and four. The sharp increase was followed by a plateau in immobility from 
intervals four through eight. On the other hand, D2 mice displayed higher initial levels of 
immobility, which shifted more gradually during testing as compared to the B6 mice. At 
individual 30 s blocks, there were very few differences by age within strains, but there 





Figure 8. Time spent below threshold (immobility) in the tail suspension test by strain, age, and 30 second interval. Data are presented 
as means ± SEM. The following groups were different at the level, p < .05: Interval 1: D2 4wk > all, D2 6wk, 8wk > B6 6wk, 8wk; 
Interval 2: D2 4wk > all; Interval 4: B6 4wk > D2 6wk, B6 8wk > D2 6wk, 8wk; Interval 5: B6 all > D2 8wk; Interval 6: B6 6wk > 
D2 8wk, B6 8wk > D2 6wk, 8wk; Interval 7: D2 4wk > D2 8wk, B6 8wk > D2 8wk; Interval 9: B6 6wk > B6 8wk, B6 6wk > D2 
6wk; Interval 10: B6 6wk > D2 8wk, D2 4wk, 6wk > D2 8wk; Interval 11: B6 4wk > B6 6wk, B6 4wk > D2 6wk, 8wk, D2 4wk > D2 
8wk; Interval 12: D2 4wk > B6 4wk, D2 4wk > D2 6wk, 8wk. 4 wk = four weeks of age, 6 wk = six weeks of age, 8 wk = eight weeks 





 Overall time below threshold.  ANOVA did not find an effect of strain on the total 
time spent immobile during the tail suspension test, F (1, 51) = .647, p = .425. However, 
there was a significant effect of age, F (2, 51) = 6.845, p = .002. Post hoc testing 
indicated that 4wk mice spent more time immobile than 6wk or 8wk mice, but the 6wk 
and 8wk mice did not differ. ANOVA also revealed a significant strain by age 
interaction, F (2, 51) = 4.947, p = .011. (See Figure 9.) Analysis of simple effects showed 
that there were no differences among B6 mice based on age. On the other hand 4wk D2 
mice spent more time immobile than did their 6wk and 8wk counterparts, who did not 
differ. Comparing the two strains, B6 and D2 mice did not differ at 4wk or 6wk, but 8wk 




Figure 9. Total time spent bellow threshold (immobility) during the tail suspension test 
by strain and age. Data are presented as means ± SEM. Groups that do not share a 
common lowercase letter are different at the level, p < .05. 4 wk = four weeks of age, 6 




Discussion and Conclusion 
Discussion of Results of Experiment 1 
 Examining the effects of acute administration of CDZ on B6 and D2 mice in the 
elevated zero maze, we found strain differences on all measures, which are similar to 
those previously reported (Tarantino et al., 2000; Cook et al., 2001). On the other hand, 
we did not find CDZ to affect activity or latency to enter an open quadrant. Previous 
reports on the effects of CDZ on activity and latency in the EZM are variable, and a 
number of authors do not include these measures at all. None the less, it seems that CDZ 
generally increases or has no effect on activity and either decreases or is without effect on 
latency (see Table 2). Increased latency is indicative of a heightened anxiety-like state; 
thus, it is somewhat surprising that CDZ does not produce a consistent decrease in 
latency. However, this measure has been previously noted as being quite variable and 
difficult to interpret (Matto et al., 1997).  
 Considering the principle measure of anxiety-like behavior, time spent in the open 
quadrants, we did see an effect of CDZ. Oddly, none of the doses tested differed from the 
saline control, but 7.5 mg/kg of CDZ produced an axiolytic effect in comparison to 
animals administered 2.5 or 5 mg/kg. While the drug by strain interaction was not 
significant, visual inspection of the data suggest that the drug treatment effect was largely 
due to CDZ having an anxiolytic effect in D2 mice but no effect in B6 mice. (See Figure 
1.) This notion is supported when separate one-way ANOVAs were performed for each 
strain. While the number of studies that have examined the effects of CDZ on mice in the 
EZM is limited, most have found an anxiolytic effect (see Table 2). To our knowledge 




Mathiasen and colleagues (2008). They found CDZ to have no effect in D2 mice but an 
axiogenic effect in B6 mice at a dose of 20 mg/kg. However, looking at their data overall, 
it seems this may be an artifact of a sedative effect. Interestingly, when testing these 
strains on the EPM, CDZ had no effect on B6 mice but an anxiolytic effect in D2 mice 
(Mathiasen et al., 2008), which is similar to what we have found. Other studies of B6 
mice in the EPM also indicate that CDZ is without effect on this strain (Rodgers et al., 
2002; Clément et al., 2009; Lalonde and Strazielle, 2010), but exceptions do exist 
(Belzung et al., 2000; Paterson et al., 2010). Many authors have attributed this lack of 
response to a floor effect as B6 mice generally exhibit a low level of anxiety-like 
behavior, but there is evidence that the differential response to CDZ between B6 and D2 
mice may be related to differences in GABAergic transmission (Hitzemann and 
Hitzemann, 1999). Considering this, it would be helpful to examine the differences 
between strains more thoroughly using receptor specific drugs and additional measures.  
 Interestingly, Rodgers and colleagues (2002) have additionally reported that 
129S2/Sv mice are also unresponsive to the effects of CDZ in the EPM. This, with the 
present findings and those of others, has major implications for the study of 
benzodiazepines using transgenic mice as they are frequently produced using B6 
blastocysts and 129 embryonic stem cells. While this highlights the importance of 
considering strain effects in pharmacological research, it also suggests that expanded 
pharmacological phenotyping of inbred strains could lead to a better understanding of the 






Discussion of Results of Experiment 2 
 In order to characterize the effects of chronic administration of SNRIX in mice, 
we administered SNRIX daily from PND 60 – 89. Beginning at PND 90 animals began a 
four day battery of behavioral testing. Behavior was assayed using the following tests: 
EZM, open field, hotplate algesia meter, light/ dark box, acoustic startle/ prepulse 
inhibition, conditioned fear, and the tail suspension test. To determine if these effects 
would vary according to strain and sex, male and female B6 and D2 mice were used. For 
clarity of presentation, the results from each of these tests are discussed individually. 
Body Weight 
 The body weight of both sexes and strains generally increased throughout the 
course of the experiment, and differences were overall, generally small. Although some 
differences were found to be statistically significant in the present study, the greatest 
difference between means observed at the same time point (between B6 females and D2 
males at PND 60) was only 5.02 g. Strain differences in body weight are often 
inconsistent, for example some have found B6 mice to weigh more than D2 mice (Liu 
and Gershenfeld, 2003), while others have found the opposite (Morris et al., 1999). More 
interestingly, we did not find an effect of SNRIX on body weight. We are unaware of any 
reports of the effects of SNRIX on body weight in mice. However, ten days treatment 
with SNRIX in sham operated female bulbectomized rats decreased body weight 
(Oliveira et al., 2004), but had no effect on body weight in male rats treated for 21 days 
(Xu et al., 2003). Drugs acting on monoamine systems are known to affect appetite, 
feeding behavior, and the regulation of body weight, and the effects of antidepressant 




to what degree the regulation of body weight is similar between clinical and preclinical 
populations. However, our failure to find an effect of SNRIX on body weight 
corresponds with reports that SNRIX does not affect weight gain in clinical populations 
(Deshmukh and Franco, 2003). As the effects of antidepressant drugs on body weight can 
exert considerable influence on patient compliance and are of particular concern for the 
treatment of patients with comorbid obesity-related diseases (Deshmukh and Franco, 
2003), further investigation would be worthwhile. 
Elevated Zero Maze 
 Extending the pharmacological characterization of the EZM in mice was a 
primary goal of this experiment. Therefore, mice were tested on this measure the first day 
following SNRIX administration. Increases in the percentage of time spent in the open 
quadrants of the elevated zero maze is considered to reflect an anxiolytic effect. We 
found that B6 mice spent a greater percentage of time in the open quadrants than D2 
mice, which concurs with previously reported findings (Cook et al., 2001). However, we 
did not find a significant effect of SNRIX. Similarly, acute treatment with SNRIX has no 
effect on behavior in the EZM in female NMRI mice (Troelsen et al., 2005). 
Interestingly, Troelsen et al. (2005) found duloxetine, another SNRI, to have no effect in 
mice on the EZM when administered acutely but to have an axiolytic effect after chronic 
administration. There are numerous possibilities for the difference between the effects of 
these two drugs, but duloxetine does have a greater affinity for the norepinephrine 
transporter (NET) at lower doses compared to SNRIX (Troelsen et al., 2005). However, 
further studies would be needed to determine what effect this might have. The EPM, from 




effects of antidepressant drugs. Chronic administration of SNRIX in sham operated 
female bulbectomized rats is without effect on behavior in the EPM (Oliveira et al., 
2004). Likewise, imipramine (Cole and Rodgers, 1995), desipramine (Gobshtis et al., 
2007), fluvoxamine (Rodgers et al., 1997), paroxetine (Goeldner et al., 2005), and 
bupropion (Carrasco et al., 2004) have all been found to have no effect on mouse 
behavior in the EPM. On the other hand, in mice, fluoxetine has been shown to have an 
anxiogenic effect when administered chronically but an anxiolytic effect if administered 
acutely (Goeldner et al., 2005), still yet others have found acute administration of 
fluoxetine to be without effect (Holmes and Rodgers, 2003). 
 Similar to the percentage of time in the open, we did not find an effect of SNRIX 
on activity or latency to enter an open quadrant in the EZM. Considering other 
antidepressants, acute administration of desipramine (Gur et al., 2007), amitriptyline, 
citatlopram, fluoxetine, paroxetine, and venlafaxine (Toelsen et al., 2005) are without an 
effect on activity or latency in mice on the EZM. However, with duloxetine, Troelsen and 
colleagues (2005) found acute, but not chronic, administration increased latency while 
chronic, but not acute, treatment increased activity in female NMRI mice. Although we 
did not find an effect of SNRIX on these measures, we did find a main effect of strain for 
activity and a strain by sex interaction for latency. B6 mice were more active than D2 
mice. With regards to latency, male B6 and D2 mice did not differ, while female D2 mice 
displayed a greater latency than their B6 counterparts. While the relationships between 
strains on these measures concur with those previously reported, the sex differences seem 




 Others have suggested that the EZM may be a useful test to detect delayed effects 
of antidepressants (Troelsen et al., 2005). However, our data suggest that chronic SNRIX 
is without effects on behavior in the EZM. Generally speaking, both the EZM and the 
EPM have not demonstrated a robust ability to detect the effects of antidepressant agents, 
with negative or conflicting results frequently being obtained (vide supra). Further, the 
elevated plus maze has been shown to be highly sensitive to slight environmental 
differences (Whalsten et al., 2003). These points and our finding suggest that elevated 
maze tests of anxiety-like behavior are not a highly efficient method of investigating the 
effects of antidepressant drugs and a larger number of animals may be needed to achieve 
the power necessary to detect effects if they exist. 
Open Field 
 We found a significant interaction between sex and strain and no effect of 
treatment with SNRIX on the total distance traveled in the open field. D2 males and B6 
mice of either sex did not differ, but all traveled more than D2 females. This is similar to 
a previous report that B6 mice travel a greater distance than do D2 mice, however only 
males were examined (Liu and Gershenfeld, 2003). Reports of the effects of SNRIX in 
mice on this measure vary greatly with strain. In B6 mice an acute dose of 40 mg/kg 
SNRIX, but not lower doses tested, increased distance traveled (Kos et al., 2006). On the 
other hand, acute doses of SNRIX as low as 2.5 mg/kg in NMRI mice (Brocco et al., 
2002) and 16 mg/kg in swiss mice (Redrobe et al., 1998) increase distance traveled in the 
open field. Still yet, using knockout mice maintained on a mixed B6 129SvEv 
background, it has been reported that in the wild-type controls 20 mg/kg SNRIX 




produced a decrease in the distance traveled (Mitchell et al., 2006). Our failure to find an 
effect of SNRIX in B6 mice may due to the highest dosage we tested, 30 mg/kg, being 
too low to elicit an effect or possibly due to a difference between chronic and acute 
treatment in this strain. Such variation between strains in the effects of SNRIX highlights 
the importance of strain selection in pharmacological research, especially when 
transgenic animal models are used. 
 We additionally found an interaction between sex and strain on the frequency of 
rearing. B6 females and D2 males reared the most followed by B6 males and D2 females. 
This finding is contrary to another that found B6 males to rear more frequently than D2 
males, but females were not tested (Liu and Gershenfeld, 2003). We further found an 
effect of sex on the habituation ratio, with males exhibiting a greater degree of 
habituation to the open field than females, and an interaction between strain and sex on 
the percentage of time spent in the corners of the arena. B6 males and females spent the 
most time in the corners followed by D2 males and then D2 females. We did not find any 
effects of SNRIX treatment on the frequency of rearing, habituation ratio, or percentage 
of time spent in the corners of the arena and are unaware of any previous reports of the 
effects of antidepressant drugs, strain, or sex on these measures.  
 We found the percentage of time spent in the center of the arena, which is 
considered a measure of anxiety-like behavior, to vary with strain, sex, and SNRIX 
treatment. (See Figure 2.) B6 mice spent a greater percentage of time in the center of the 
arena than did D2 mice irregardless of sex or drug treatment. SNRIX had no effect on D2 
mice of either sex, and B6 mice of both sexes that were administered 10 mg/kg SNRIX or 




to spend a greater percentage of time in the center of the arena, while B6 females given 
30 mg/kg SNRIX tended to spend less time in the center as compared to their respective 
saline controls. This suggests that chronic administration of 30 mg/kg SNRIX produces 
an anxiolytic effect in B6 males but an anxiogenic effect in B6 females. We are unaware 
of any previous reports on the effects of SNRIX on this measure. However, others found 
that chronic fluoxetine treatment reduces center time in B6 males but is without effect in 
D2 males, although the effect in B6 males was confounded with an effect on activity in 
the open field (Dulawa et al., 2004). We did not find a significant effect of SNRIX on the 
percentage of total distance traveled in the center of the arena. This along with the lack of 
an effect of SNRIX on the total distance traveled suggests that the effect of 30 mg/kg 
administration on time spent in the center of the arena is not due to differences in activity 
levels. Still, further investigations would be needed to delineate causal factors behind the 
strain and sex differences observed here. 
Hotplate 
 We only found a significant effect of strain on hotplate latency, with D2 mice 
exhibiting a longer latency to display a pain response than B6 mice, which concurs with 
previous reports (Mogil et al., 1999). We did not find an effect of SNRIX administration. 
In Swiss mice it has been reported that an acute dose of 16 mg/kg SNRIX is without 
effect on hotplate latency (Ripoll et al., 2006). However, acute SNRIX administration has 
been shown to increase latency in ICR mice with an estimated ED50 of 46.7 mg/kg 
(Schrieber et al., 1999). Similarly, fluvoxamime and citalopram, but not escitalopram, 
have been reported to increase hotplate latency when administered acutely (Schrieber et 




study were too low to elicit an effect. However, the lack of an effect of SNRIX in the 
current study could be due to chronic as opposed to acute drug administration. 
Unfortunately, acute administration was not examined here, and we are not aware of any 
previous investigations of the effects of chronic administration of antidepressant drugs on 
hotplate algesia.  
Light-Dark 
 The percentage of time spent in the light half of the light-dark box is generally 
recognized as a measure of anxiety-like behavior. We found a significant strain by sex 
interaction. B6 males and females did not differ and spent a greater amount of time in the 
light side of the apparatus than did D2 mice. Further, D2 males spent more time in the 
light than did D2 females. This finding generally concurs with a previous report that male 
B6 mice display less anxiety-like behavior than D2 males (Liu and Gershenfeld, 2003). 
Additionally, our results indicated a trend towards an interaction between strain, sex, and 
SNRIX administration, but this did not reach significance (F (2, 119) = 2.798, p = .065, 
ES: f = .217; Figure 3). B6 males in the saline group spent a greater percentage of time in 
the light than did any other treatment group. B6 females and D2 males did not differ, 
while B6 mice of both sexes and D2 males spent more time in the light than did D2 
females. Administration of SNRIX was without effect on D2 mice of both sexes as well 
as B6 females. On the other hand, both doses of SNRIX tested produced an equivalent 
anxiogenic response in B6 males as compared to their respective saline control. We are 
not aware of any previous reports on the effects of SNRIX in the light-dark box in mice. 
However, in male rats, acute or seven days treatment with 20 mg/kg SNRIX results in an 




(Nowakowska et al., 2003). The effects of the acute administration of other 
antidepressant agents on behavior in the light-dark box in mice have been previously 
described; however, the reported results have been divergent. Paroxetine (Hascoët et al., 
2000) and the tricyclic antidepressant, dothiepin, (Bourin et al., 1996) have an anxiolytic 
effect, but fluoxetine, imipramine, and maprotiline are without effect (Bourin et al., 
1996).  
 We found a significant interaction between strain and sex on the distance traveled 
in the light/ dark box. B6 females traveled the greatest distance followed by B6 males and 
D2 males, while D2 females traveled the least distance of all. Additionally, main effects 
of strain and sex were found on the percentage of total distance traveled occurring in the 
light side of the apparatus. B6 were more active than D2 mice, and males were more 
active than females in the light compartment. We found no effect of SNRIX 
administration on either the total distance traveled or the percentage of total distance 
traveled occurring in the light. 
Acoustic Startle/ Prepulse Inhibition 
 We found a significant interaction between strain and sex on the response to the 
120 db startle stimulus. B6 males exhibited a greater response than did B6 females 
followed by D2 males and females, which did not differ. This finding generally concurs 
with others that have found B6 mice to display a greater startle response than D2 mice 
(Paylor and Crawley, 1997; Willott et al., 2003), but where examined no effect of sex 
was observed (Willott et al., 2003). Main effects of strain were found on the percentage 
of prepulse inhibition of the startle response at 70, 80, and 85 db. In all cases B6 mice 




differences in prepulse inhibition have varied. Our findings concur with those of one 
report (Willott et al., 2003), but an opposite relation between these strains has also been 
reported (Paylor and Crawley, 1997). It is possible that these differences in results are 
due to differences in apparatus designs and configurations, as they vary considerably 
between studies. In the present study, a main effect of sex was found on prepulse 
inhibition at 80 db, but not 70 or 85 db, with males exhibiting a greater degree of 
inhibition than females. Additionally, we observed a trend towards an effect of SNRIX 
treatment on prepulse inhibition at 70 db (F (2, 123) = 2.832, p = .063, ES: f = .215), and 
a significant effect at 80 db. (See Figure 4.) In both cases, administration of 30 mg/kg, 
but not 10 mg/kg, SNRIX increased the percentage of prepulse inhibition relative to 
saline controls. We are not aware of any previous reports of the effects of SNRIX on 
acoustic startle or prepluse inhibition. However, serotonin agonists are generally without 
effect in B6 mice tested in a MDMA disrupted prepulse inhibition paradigm (Duwala and 
Geyer, 2000). Similarly, citalopram and buproprion have no effect on prepulse inhibition 
and decrease the acoustic startle response, while desipramine increases prepulse 
inhibition and decreases the startle response in rats treated with amphetamine (Pouzet et 
al., 2005). Previous reports have indicated that the NET may play a role in acoustic startle 
and prepulse inhibition in both preclinical (Yamashita et al., 2006) and clinical 
populations (Quednow et al., 2004). It has previously been reported that chronic 
administration of 10 mg/kg SNRIX in rats inhibits the activity of the serotonin transporter 
but not the NET, while 40 mg/kg SNRIX inhibits the activity of both (Béïque et al., 
2000). If the same dose dependency exists in mice, this might provide a possible 




10 mg/kg. These reports along with our finding suggests that further investigations into 
the effects of antidepressant medications, and specifically those acting on noradrenergic 
systems, on acoustic startle and prepulse inhibition are warranted. 
Fear Conditioning 
 The measure of training suppression of activity is indicative of how successful the 
training procedure was at decreasing activity relative to baseline activity prior to the 
shock – tone pairings, with a lower value indicating greater suppression of activity and a 
value of 1 indicating no change. We found no differences between any treatment groups 
on the basis of strain, sex, or SNRIX administration for training suppression, and all 
groups displayed a reduction in activity following training (M = .355, SEM = .032). 
Context suppression of activity compares activity in the training context relative to the 
baseline activity recorded the prior day and is indicative of the strength of the association 
formed between the training context and the unconditioned stimulus (i.e. electric shock). 
We found a significant effect of strain on context suppression of activity, with B6 mice 
displaying less activity suggesting an enhanced memory of the context compared to D2 
mice, which concurs with previous reports (Logue et al., 1997; Stiedl et al., 1999; Nie 
and Abel, 2001). Additionally our finding of an interaction between strain and sex 
replicates a previous report, which found no difference between B6 males and females 
although D2 females displayed a greater inhibition of activity in the context than did their 
male counterparts (Bolivar et al., 2001). In the present study we found SNRIX to be 
without effect on context suppression of activity. We are unaware of any previous reports 
of the effects of antidepressant agents on fear conditioning. However, citalopram has 




paradigm, which does not include cued conditioning (Inoue et al., 1996). As for cued 
conditioning, we found a significant strain by sex interaction. B6 males and females, as 
well as B6 males and D2 males, did not differ in their response to the tone. However, D2 
females showed a greater reduction in activity in response to the tone than did the other 
groups. Others have reported a similar interaction where females were tested (Bolivar et 
al., 2001). However, reports on males alone are more varied with some finding no 
differences between B6 and D2 mice (Logue et al., 1997; Nie and Abel, 2001), but 
increased tone suppression of activity in B6 as compared to D2 mice has also been 
observed (Stiedl et al., 1999). Such variability in findings may, in part, be due to 
differences in the methods used to score behavior. For instance a number of authors have 
used visual determination of freezing behavior, where as we have used an automated 
system to measure general activity. Both methods have advantages; visual scoring is 
more specific, but the use of an automated system increases throughput and decreases the 
opportunity for experimenter error. Additionally, we have compared activity during 
presentation of the tone to baseline activity in the altered context while others have 
reported only activity during the presentation of the tone. Our results indicate that SNRIX 
is without effect on cued conditioning; unfortunately, we are not able to compare this 
with any previous reports. 
Tail Suspension 
 We observed a large number of mice that climbed their tails during the tail 
suspension test. A central principle of this test is that the stress of the procedure is 
inescapable (Cryan and Mombereau, 2004), and once the animal climbs its tail, this is no 




reported about tail climbing behavior, other than its occurrence. We therefore decided to 
analyze the data collected on tail climbing using the between subject factors of the study 
in a logistic regression analysis. Our analysis did not suggest that strain was predictive of 
tail climbing, which is contrary to a previous report that B6 mice climb their tail more 
frequently than D2 mice (Mayorga and Lucki, 2001). We did find that males were more 
likely to climb their tails than females, but SNRIX treatment was without a significant 
effect. Tail climbing has generally been treated as a nuisance, and some apparatus claim 
to avoid the behavior by attaching the animal‟s tail to a ring rather than a metal plate. 
However, our results and those of others (Mayorga and Lucki, 2001) indicate that this 
trait may be influenced by genetic factors and sex, suggesting that it may be worthy of 
more in depth investigation.  
 Overall, we did not observe an effect of strain on time spent immobile during tail 
suspension. Others have reported that B6 mice exhibit more immobility than D2 mice, 
although differences were small (Liu and Gershenfeld, 2003). We did not find an effect 
of SNRIX on immobility. Others have reported that in mice acute administration of 
SNRIX decreases immobility in the tail suspension test (Millan et al. 2001; Liu et al., 
2003; Kos et al., 2006) and the forced swim test (Redrobe et al., 1998; David et al., 2001; 
Millan et al., 2001; Berrocoso et al., 2004). We are unaware of any previous reports of 
the effects of chronic SNRIX administration in mice. However, in rats, administration of 
SNRIX for 7 days (Nowakowska et al., 2003; Nowakowska and Kus, 2005) or 10 days 
(Oliveira et al., 2004) decreases immobility, but administration for 14 days (Nowakowska 
et al., 2003; Nowakowska and Kus, 2005) or 24 days (Connor et al., 2000) has no effect. 




of subjects tested. In addition to dropping the data for 31.2% of the animals in the study 
due to tail climbing, the data for 10 additional animals was lost due to a malfunction of 
the computer used to operate the tail suspension equipment resulting in some treatment 
cells being comprised of as few as four animals. Thus caution should be used in the 
interpretation of these results. 
Summary and Implications of Findings in Experiment 2 
 We have demonstrated here that the behavioral effects of chronic administration 
of SNRIX in mice vary by test, strain, and sex. As has been discussed elsewhere (Dulawa 
and Hen, 2005), few behavioral tests have been shown to be sensitive to chronic 
administration of antidepressant drugs. Our results reinforce this notion, as we did not 
find effects of SNRIX using the EZM, hotplate algesia meter, fear conditioning, or the 
tail suspension test. However, we have found that treatment with SNRIX was without 
effect in D2 mice, but produced an anxiolytic effect in B6 males and an anxiogenic effect 
in B6 females in the open field. On the other hand, our results suggest a non-significant 
trend towards an anxiogenic effect of SNRIX in B6 males, but not B6 females or D2 
mice, in the light/ dark box. Lastly, we found that SNRIX produces an improvement in 
the inhibition of the acoustic startle response by an 80 db prepulse regardless of strain or 
sex. 
 The present findings have several implications for future research. Previously it 
has been shown that the novelty-induced hypophagia test (Dulawa and Hen, 2005) and 
the resident intruder paradigm (Mitchell and Redfern, 2005) are sensitive to chronic 
administration of antidepressant drugs. Our finding that the open field and light/ dark box 




sensitive to the chronic administration of other antidepressants. If so, this would represent 
a marked improvement in efficiency, as these tests are far less time consuming to perform 
than either of those previously suggested. Additionally, we have shown that the response 
of B6 animals to SNRIX is dependent on sex in both the open field and light/ dark box, 
which suggests that this strain may be useful for future studies on the sex dependent 
effects of antidepressant agents. Further, our data indicate that B6 and D2 strains differ in 
their response to SNRIX administration. This highlights the value of testing multiple 
inbred strains in pharmacological research and the importance of considering background 
effects when using transgenic models. Further, the difference in strain response suggests 
that the BXD recombinant inbred lines may be a good choice for mapping quantitative 
trait loci influencing the effects of antidepressant drugs. Lastly, the present findings 
underscore the need for further investigations of antidepressant drugs that consider sex, 
genetic differences, and chronic administration. 
Discussion of Results of Experiment 3 
 Noting that there is relatively little information in the literature on age-related 
behavioral differences in mice during adolescence and seeking to expand upon what is 
available, we examined the B6 and D2 mice at 4, 6, and 8 weeks of age in six behavioral 
models. We found almost all measures to vary with strain, and for the most part the 
relations observed concur with previous reports (Logue et al., 1997; Stiedl et al., 1999; 
Cook et al., 2001; Nie and Abel, 2001; Liu and Gershenfeld, 2003). Our observations 
with regard to the effect of age are far more variable. Considering the standard measures 
of anxiety-related behavior in the present study, we did not find an effect of age on the 




we did find a significant strain by age interaction on the percentage of time spent in the 
center of the open field and a trend towards an effect of age on the percentage of time 
spent in the open quadrants of the EZM. However, these two measures depict opposite 
relations between the age groups. Although not quite reaching significance (F (2, 54) = 
2.971, p = .060, ES: f = .331), 8wk mice displayed more anxiety-like activity than 6wk 
mice in the EZM, but the opposite was seen among B6 mice in the open field. (See 
Figures 5 and 6.) Looking at the literature, it seems that age-related differences in 
anxiety-like behavior differ considerably between tasks, and the patterns of variability 
between tasks differ between mice and rats.  
 We are not aware of comparable studies of rodents in the EZM, but there are a 
number of studies on age-related differences in behavior using the EPM. In mice a 
relatively consistent pattern of results is seen, with most studies finding no age-related 
differences during adolescence (Hefner and Holmes, 2007; Kota et al., 2007; Peleg-
Raibstein and Feldon, 2011) or, similar to our observations in the EZM, adolescent mice 
display less anxiety-related behavior than adult mice (Adriani et al., 2004; Oh et al., 
2009). On the other hand, The reports on rats in the EPM are more variable, finding 
adolescents less anxious than adults (McCormick et al., 2008; Doremus-Fitzwater et al., 
2009a; Kupferschmidt et al., 2010), adults less anxious than adolescents (Elliot et al., 
2004; Lynn and Brown, 2009; Lynn and Brown, 2010), or no age-related differences 
(Doremus-Fitzwater and Spear, 2007; Doremus-Fitzwater et al., 2009b; Eppolito et al., 
2010; Villégier et al., 2010).  
 In the open field, a converse relationship between rats and mice is seen regarding 




and Holmes (2007) found 8wk B6 mice to display less anxiety-like behavior than 4wk or 
6wk mice. However, Oh et al. (2009) found adolescent B6 mice to be less anxious than 
their adult counter parts while there were no age-related differences in Swiss mice. In 
contrast, reports on rats predominantly find no age-related differences in anxiety-related 
behavior in the open field (Lynn and Brown, 2009; Lynn and Brown, 2010; Li et al., 
2010), but Cao et al. (2010) has found that adolescent rats are less anxious than 
periadolescents or adults.  
 Unfortunately, we are not aware of any previous reports on age-related 
differences in the light-dark box using mice, but most studies using rats have found no 
age-related effects (Slawecki, 2005; Slawecki et al., 2006; Kupferschmidt et al., 2010). 
However, Kupferschmidt et al. (2010) did find adolescents to display a shorter latency to 
enter the light side of the light-dark box, suggesting reduced anxiety. While we did not 
include this measure in our analysis, we did find that 4wk mice traveled a greater 
percentage of distance in the light than did 8wk mice. While the interpretation of this 
measure is nuanced, it is indicative of increased activity in an aversive environment. It 
may be that in the light-dark box activity- and anxiety-related measures are more 
intertwined with regard to age. 
 If in fact anxiety models differ in their sensitivity to age-related differences in 
anxiety-like behavior between rats and mice, extrapolation of findings between species 
would be tenuous, and the selection of the appropriate behavioral model would be 
imperative to protecting against type II error. However, there are a number of factors that 
should be considered. For instance, the number of studies examining the behavior of 




considerably. Additionally, much of the available data on behavior during adolescence 
comes from pharmacological studies, and many of them either do not report baseline 
differences on the basis of age or analyze age groups separately. Thus, the comparisons 
presented above are in places based upon estimates of the data presented. Further 
complicating the issue, it seems that age-related differences may be particularly sensitive 
to test and pretest conditions. For example, Slawecki (2005) found no differences 
between adult and adolescent rats in the light-dark box under standard conditions but did 
find age-related differences when testing was performed under bright lights or when 
animals had been previously subjected to restraint stress. Unfortunately, in the end, 
further research and replication will be required to disentangle the relationships between 
these factors. 
 We also examined nociception, fear conditioning, and depression-related 
behavior. We did not see any age-related effects in the hotplate algesia test. Only a few 
studies have examined nociception during adolescence. Similar to our findings, ICR mice 
do not display age-related differences in their latency to display a pain response in the tail 
flick test or the hotplate test (Kota et al., 2007). However, adolescent and adult Sprague-
Dawley rats do not differ in the tail flick test (Conway et al., 1998), but periadolescents 
display a longer latency than do adolescents in the hotplate test (Ingram et al., 2007). 
While nociception is not directly linked to anxiety-like behavior, it can be indicative of 
gross abnormalities, and the finding of age-related differences in nociception during 
adolescence could have implications for pain management in clinical settings. 
 In fear conditioning, we did not see any age related-differences in training 




others have found no difference in training acquisition in B6 mice (Pattwell et al., 2011; 
Peleg-Raibstein and Feldon, 2011) or rats (Land and Spear, 2004; Esmorís-Arranz et al., 
2008). On the other hand, Hefner and Holmes (2007) observed 4wk B6 mice to display 
more freezing at trial 4, but no differences in previous trials. With regards to conditioning 
to the context, findings are variable. Some have found no age-related differences in B6 
mice (Peleg-Raibstein and Feldon, 2011) and rats (Land and Spear, 2004), but others 
report greater contextual conditioning in adolescent rats as compared to young adults 
(Esmorís-Arranz et al., 2008). It seems that contextual conditioning may be particularly 
sensitive to the exact age at which conditioning occurs. Pattwell et al. (2011) found no 
differences in contextual conditioning at PND 23-27 and PND 49-70, but a deficit at 
PND 29-33 and a slight deficit at PND 35-39 in B6 mice. Interestingly, when animals 
were trained at PND 29-33, they showed a deficit when contextual conditioning was 
tested under standard procedures, but showed normal contextual conditioning when 
tested 14 days later with no additional training (Pattwell et al., 2011). The findings with 
regard to conditioning to the cue are quite variable as well. Some have found no age-
related differences in B6 mice (Pattwell et al., 2011) and rats (Land and Spear, 2004), but 
conflicting reports also exist finding adolescent (Hefner and Holmes, 2007) and adult 
(Peleg-Raibstein and Feldon, 2011) B6 mice to both show superior conditioning to the 
cue. We are not aware of any previous reports on age-related differences in fear 
conditioning in mouse strains other than B6. Thus, we are unable to compare our null 
findings in D2 mice directly to any other reports. Considering the differences between 
inbred strains among adults, it may be the case that if additional strains were examined 




 In the tail suspension test, we found no age-related differences in B6 mice, but 
4wk D2 mice spent more time immobile than 6wk and 8wk D2 mice. Additionally, 
looking at the progression of immobility across testing, we found that B6 mice displayed 
a low initial immobility that quickly increased to a plateau. On the other hand, D2 mice, 
especially in the 4wk group, showed higher initial immobility that increased more 
gradually. We are not aware of any previous studies looking at age-related differences in 
D2 mice in depression-related behavior, but a number of reports on B6 mice are 
available. In contrast to our findings, all previous reports have found age related 
differences in B6 mice in the tail suspension test (Mason et al., 2009) and the forced 
swim test (Hefner and Holmes, 2007; Oh et al., 2009; Mason et al., 2009). It is not clear 
why we did not see an age related effect in B6 mice, but our finding of increased 
immobility in 4wk D2 mice concurs with others who have found a similar age 
relationship in B6 and BALB/c mice in the TST (Mason et al., 2009) and in B6, BALB/c, 
and B6x129s5 F2 mice in the forced swim test (Hefner and Holmes, 2007; Mason et al., 
2009). However, the reported age differences among mice are not entirely consistent. 
Some have reported no differences in the tail suspension test in B6x129s5 F2 mice 
(Mason et al., 2009) and in the forced swim test using Swiss mice (Oh et al., 2009). Still 
yet, others have reported B6 adults (Oh et al., 2009) and Swiss adults (Moreira et al., 
2005) to spend more time immobile than there adolescent counterparts. None the less, the 
variability between strains with regards to age-differences suggests that the development 
of depression-related behavior is likely influenced by genetics, and further experiments in 
this area may shed light onto the risk factors associated with pediatric/ adolescent 





 The experiments presented here are, of course, not without limitations. 
Experiments 1 and 2 sought to more fully characterize the EZM by examining the acute 
effects of CDZ and the effects of chronic administration of SNRIX in B6 and D2 mice. In 
all actuality, this is far from a full pharmacological characterization. Our laboratory is 
working to extend the findings of Experiment 1 to include two additional classes of 
anxiolytics, buspirone and fluoxetine, and female animals as well. However, 
unfortunately, difficulties producing mice prevented full data sets from being available. 
With regards to Experiment 2, the method of drug administration is less than ideal. 
Animals were injected daily. Thus, it can be assumed that an effect of handling and 
injection stress was present, although experienced by all animals. Additionally, drug 
administration was ceased during behavioral testing. This decision was made largely due 
to the amount of drug we were provided by the pharmaceutical company and the time 
constraints presented by the behavioral battery. Although we did find effects of SNRIX 
administration as late as the third day of testing, it must be acknowledged that the levels 
of drug on board can not be assumed to be consistent across behavioral tests. Future use 
of osmotic mini pumps may well be preferable, as it would greatly diminish such 
concerns. In both Experiments 2 and 3, Animals were tested on a battery of several tests 
over the course of four days. We are not able to say what effect prior testing had on 
subsequent testing. However, previous use of this battery in a large mutagenesis screen 
suggests that phenotypes identified with sequential testing in early pedigrees are reliably 
reproduced with naïve testing in later pedigrees (Cook et al., 2007). The primary benefit 




wide range of behaviors. However, it cannot be discounted that the testing history of the 
animals should be considered. Lastly, in all three experiments, we have only examined 
two inbred strains. It would be ideal to extend the current experiments to include 
additional inbred strains, and examining the 129 strains would be of particular value 
given their regular use in the generation of transgenic mice. 
 Looking at the experiments presented here and the literature as a whole, one of 
the most striking features is the great deal of variability seen between similar tests, 
animals, and drugs. For example, we found no effect of SNRIX in two measures of 
anxiety-like behavior (i.e. the EZM and fear conditioning) and seemingly opposite 
effects, at least in B6 males, in two other measures of anxiety-like behavior (i.e. open 
field and light/ dark). While such variability is perplexing, it does seem to be the norm in 
the literature on preclinical anxiety-like behavior. It is possible that different assays are 
measuring unique aspects of anxiety-related behavior and particular drugs and 
experimental manipulations only affect some of these. However, using factor analysis to 
compare multiple measures of anxiety-like behavior often yields results that do not allow 
for meaningful interpretation or suggest that each measure should load onto an 
independent factor (Brigman et al., 2009; Philip et al., 2010). Ramos (2008) has noted 
that the effects seen on any single measure provides only a snapshot of an animal‟s 
overall pattern of behavior, and estimates of covariance between tests are highly 
temporally and contextually dependent. Considering this, it is interesting that in the open 
field, which is nearly four times the duration of our other measures of anxiety behavior, 
we see effects of both SNRIX and age-related differences. Considering Experiment 2, 




effect of SNRIX in B6 males, but the anxiogenic effect in B6 females drops out. It may 
be the case that extending the test durations used in the other measures of anxiety-like 
behavior would aid in detecting small to moderate effects. 
 Overall, the available evidence on anxiety disorders and mood disorders in 
general, suggests they are the product of complex gene by environment interactions that 
are further shaped across development. Murine genetic models offer a unique opportunity 
to explore these relationships and address issues in the treatment of mood disorders. 
However, the nature of the experimental problem requires that factors with relatively 
small effect sizes be considered, which can be easily drowned out by experimental noise. 
Here, attempts have been made to address this by extending the baseline data available on 
anxiety-like behavior in two common inbred strains of mice, the ultimate goal being to 
further our understanding of the etiology of these disorders and improve our ability to 
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